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Peripheral neuropathies are a debilitating problem in human and animal patients resulting in diminished the 
quality of life. The current gold standard methods for repair of critical size peripheral neuropathies have 
limitations that overall diminish the quality of life for patients. The use of nerve scaffolds composed of 
synthetic polymer-based materials to heal damaged nerves has become an attractive approach in 
regenerative medicine research. Studies have shown the biomaterial characteristics of graphene oxide to 
have potential in applications for regenerating damaged peripheral nerves. Studies have also shown that 
incorporating Mesenchymal Stem Cell (MSC) therapies into neural scaffold designs can significantly 
improve the quality of tissue healing as well. The hypothesis of this study is that a novel synthetic thin film 
composed of electro spun polycaprolactone (PCL) and modified with surface coating of Graphene Oxide 
(GO) and cultures of Human Mesenchymal Stem Cells (hMSC) will have the potential to regenerate a 
critical size peripheral nerve defect. The first objective studied the potential cytotoxic effect of graphene 
surfaces with different oxidative group saturation levels to rat adipose derived stem cell (rADSC) cultures. 
This objective also manufactured PCL materials of fibrous and smooth surface topographies using both 
electrospinning and polymer-drop techniques. The second objective assessed the In-vitro capabilities of GO 
surface modifications of both fibrous and smooth surface PCL material templates seeded with adipose 
derived hMSCs for materials effectiveness in supporting and guiding trans-differentiation of hMSC into a 
Schwann like cell lineage. The final objective involved the development of an approved critical nerve defect 
model in Rats to assess the In-vivo performance of electro-spun PCL films with GO surface modification 
and hMSC platform to stimulate nerve regeneration at a critical nerve defect. The degree of nerve 
regeneration was determined by exogenous detection of gait patterns in the rats during nerve repair and 
tissue identification/ measurements thru Histology sections. This study to date has shown that neural wraps 
composed of electro-spun PCL surface coated with GO can support the hMSC in both static and trans-
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1.1 Biomaterials for Biomedical Applications 
Our current definition of a biomaterial is a natural or synthetic material intended to interface with biological 
physiological systems to treat or replace tissue/organ functions in the body [1]. Biomaterials are an essential 
component that must be incorporated into the design of medical devices so that when such devices interact 
with surrounding tissue/extracellular matrix (ECM) they stimulate the surrounding native tissue to behave 
in either a state of regenerative potential or an inert homeostasis. The effectiveness of a biomaterial to 
stimulate tissue into a regenerative state is based on the materials ability to support proliferation, 
migration/orientation, and differentiation of cells while ensuring that material structural failure, foreign 
body signaling, and toxicity are minimized. This can be further characterized by understanding how 
biomaterial properties like surface chemistry, surface topography, bulk porosity/geometry, and by-products 
created thru biological degradative processes can stimulate particular cellular chemical and 
mechanobiological pathways.  
There is currently on going and rapidly expanding research in the field of biomaterials to understand how 
these characteristics of biomaterials can target specific regenerative cellular pathways to become active and 
how they could further enhance tissue regeneration. Such research has also been discussed for the design 
of biomaterial scaffolds for the application of regenerating severe peripheral neuropathies in the hopes of 
improving healing time and the quality of regenerated peripheral nerve tissue [2]. 
1.1.1 Biocompatibility Assessment 
The term biocompatibility is defined by D.F. Williams as “the ability of a material to perform with an 
appropriate host response in a specific application” [3]. The Science community has discussed throughout 
the conception of biomaterials as to how to characterize biocompatibility of a material and to what degree. 
Thru decades of research in both In-vitro and In-vivo models, the term can be subdivided into four individual 
categories of analysis that must be reviewed for a material to be labeled as biocompatible: toxicology, 
reaction to extrinsic microorganisms, mechanical effect, and cell-biomaterial interactions [4]. This has led 
to the development of both In-vitro and In-vivo methods for the assessment of each subdivision and the 
development of standardized procedures designed to insure these methods answer with high certainty the 
public concern that a device or material will improve and ensure public safety. The selection of In-vitro 
methods should consider the type of biomaterial and biological components being assessed for cytotoxicity 
to determine any potential toxic mechanisms or material property effects due to reaction with the assays 
involved that could give null or false readings. Most of these procedures are standardized by international 
agencies such as the International Organization for Standardization (ISO) section 10993 “Concerning 




while other agencies will regulate or enforce these standards such as the United States Food and Drug 
Administration (USFDA) Code of Federal Regulations (CFR) Cha 1- Subchapter H [5].   
1.1.1.1 In-vitro Models 
The evaluation of cytotoxicity in biomaterials can be simplified by observing how target cells or tissue will 
react in direct or indirect contact with biomaterials. If, under controlled conditions, cells react to the material 
with normal cell behavior and function such as cell adhesion, proliferation, migration, and differentiation 
we can conclude that the cell’s physiological system is normal or homeostatic. However, if under these 
same conditions’ cells react with behaviors indicative of cell stress, or cell death we can conclude that the 
material can induce some toxic or stressful effect on the cells. In-vitro models have a distinct advantage 
due to the methods employed and the environments that can be controlled. Under controlled laboratory 
conditions, specific variables related to cell-material interaction cytotoxicity can be analyzed under 
reproducible and sensitive conditions. The methods utilized are therefore more precise, accurate, and 
reproducible to strengthen statistical models. In-vitro methods can result in both qualitative and quantitative 
data. Qualitative methods assess the state of cellular health by evaluating the morphology of cell lines after 
exposure to the material and grading the health of cells based on the amount of cell death, cytoplasmic 
granule formations, and the percentage of cells non-adhered to the material. Quantitative methods determine 
the number of viable cells based on the presence of nucleic acid, metabolic by-products, or the expression 
of surface adhesion markers. These methods follow ISO standards under section 10993 part 5 which 
stipulates the different methods for collecting cytotoxicity data In-vitro and can be further subdivided into 
more specific methods of cell-material interactions [5, 6]. 
In-direct contact method involves either Agar or Filter Diffusion Tests. In both cases, a monolayer cell 
culture is grown in a culture environment while the physical biomaterial is placed in the same culture 
environment but is separated by an Agarose gel or cell filtration film as a barrier diffusion model. Over a 
designated period of culture, the material might diffuse compounds through the Agar membrane into the 
culture environment where it will make direct contact with the cell line. The purpose is to observe whether 
the cell lines can be induced towards a cytotoxic state due to direct exposure to potentially toxic 
material/protein loading components, nanomaterials and the agglomerates, and degradation agents that have 
leached from the material into the culture environment. The advantage of this system is that it is controlled 
to look at toxicity of cells specific to the leeched components from the materials, while qualitative and 
quantitative assays have their additional sensitivity, and accuracy parameters for identifying the specific 
toxic components responsible. The disadvantage is that it does not include toxic effects due to mechanical 
trauma, mechanobiological pathways, and cell-material interactions. This must be further analyzed with a 




Direct contact method involves direct contact of cells with the substrate with no separation of the cell 
monolayer to the biomaterial. The cell line is cultured in direct contact with the material which adds the 
variable of cell-material reactivity as a variable in cytotoxicity as well as the physicochemical variables 
specific to in-direct methods of cytotoxicity analysis. This creates a more complex model of analysis due 
to the higher degree of variables that can elicit a toxic response to the cell. This may make it more difficult 
to determine, with certainty, what the exact causes of cytotoxicity are and thus it is often necessary to 
confirm with additional testing. There is a concern in establishing standard testing methodologies for direct 
contact methods due to the nature of the materials (3D structure, Bio-resorption, Nano-topography, etc.) 
being tested and the different cell-lines used, adding even more potential variables of toxicity. The 
advantage of this method is that it is inexpensive, quick, and sensitive to these toxicity factors. If the 
material under a direct contact model does not elicit a cytotoxic effect to the cell-lines, then an initial 
conclusion would be that both the physicochemical and mechanical properties of the material are not 
cytotoxic to the cell lines. It should be further confirmed with repeated direct contact tests utilizing different 
cytotoxicity assays, but the potential statistical power of a single direct contact test performed correctly 
could conclude with high certainty whether a material is cytotoxic or not.     
Extract Dilution (Elution) test involve suspending a sample of the material in a physiological solution that 
will extract elution solvents present in the material during the production phase while minimizing physical 
and chemical damage to the material as well as being compatible with the cell lines. Elution samples are 
then added to mono-layered cell cultures for 24-48 hours before toxicity assays are introduced. Very similar 
to the indirect contact method, this method will often result in a consistent toxicity pattern in cell culture 
due to minimal variability of elution solvents that are present in the material during production. While a 
good first approach to determine initial cytocompatibility of the material, it suffers the same disadvantages 
as an indirect method [5, 6].   
Qualitative assessment of cytotoxicity in In-vitro studies involve the use of methods that are labeled as 
categorical variables to determine if cytotoxicity is present in cell-lines. This form of assessment will often 
use stains for viable and non-viable cells under fluorescent microscopy (FM) as a morphological indicator 
of cell health. Some of the more common viable stains in use involve high affinity towards specific cell 
structures such as the nucleotides within the nucleus, ATP and coenzymes in the mitochondria, permeability 
of the cell membrane, or cytoplasmic proteins/cytoskeletons. The intensity of the stain is correlated to the 
number of these structures present in the cell and combined with all other stained cells gives an overall 
indication of viability for the entire culture. Some examples of common viability assays utilized for In-vitro 





Table 1.1 In-vitro viability assays 
Viability Stains Stain mechanism  Assessment            
(live cells/dead cells) 
4`,6-diamidino-2-
phenylindole (DAPI) 
Fluoresces to covalent binding to DNA and 
RNA sections Dead cells 
 
 
7-Aminoacetinomycin D Fluoresces to covalent binding of cytosine, and 
guanine sites of DNA Dead cells 
 
 
Calcein AM  Intracellular esterases excitation  
Live cells  
 
Propidium Iodine Fluoresces to covalent binding of DNA and 
chromosome bases  Dead cells 
 
 
MTT Bulk tetrazolium salt dehydrogenase with 
NADPH formazan excitation Live cells 
 
 
WST-8 Soluble tetrazolium salt dehydrogenase with 
NADPH formazan excitation  Live cells 
 
 
Thymidine [H3] radioactive neucleoside binding to DNA 





Viability data can also be acquired by observing cell morphology and death or lysis under (FM), light 
microscopy (LM), or scanning electron microscope (SEM) to determine the viability of cells based on 
physical cell characteristics such as cell shape size, spreading, or density. Fluorescent stains can also be 
used for this type of assessment if stains are sensitive enough to differentiate between cell structures such 
as the use of nuclear stains coupled with cytoplasmic counter stains. Cells suspended in media that exhibit 
spherical shapes and minimal spreading on surface after 24-48 hours of incubation are often key indicators 
of apoptotic behavior, while viability stains will confirm whether cell integrity, DNA, and cytoplasmic 
environments are stable. This type of analysis is often categorized into a graded scale assessment of 
cytotoxicity. Based on previous research involving similar cell lines, these types of observations can 
establish a standard scoring system for cell cytotoxicity as the primary method for assessing the health of 
cells based on cell morphology alone[7]. Other qualitative methods involve real-time tracking of the cells 
by implanting fluorescent protein or radioactive isotope components or by labeling protein/gene sequence 
markers using fluorochrome labeled antibodies that bind to these specific markers, which can then be 







Table 1.2 Degrees of Cytotoxicity in the Agar Diffusion and Direct Contact Tests 
Degree CYTOTOXICITY DESCRIPTION OF THE CYTOTOXICITY AREA 
0 Absent Absence of decolorization around or under the sample 
1 Slight Decolorization limited to the area under the sample  
2 Mild The size of the decolorization area from the sample is less than 
0.45 cm 
3 Moderate 
The size of the decolorization area from the sample is less than 
0.45 cm and 1.0 cm 
4 Severe 
The size of the decolorization area from the sample is greater 
than 1.0 cm, but does not involve the entire plate 
Source: Vidal, M. N. P., and J. M. Granjeiro. 2017. “Cytotoxicity Tests for Evaluating Medical Devices: An Alert for the Development of 
Biotechnology Health Products.” Journal of Biomedical Science and Engineering 10 (09): 431–43 
 
Caution must be reserved when interpreting qualitative data as it will often introduce debate among experts 
as to what the cells’ morphology indicates about the health of the cells. This also is present when comparing 
fluorescent stains to control parameters to determine if any specific toxicity pathway or mechanism has 
activated in the cell-line.  This is particularly true for unspecified cell-lines that are capable of differentiating 
into multiple cell lineages and are thus capable of activating many different cytotoxicity pathways.  It is 
important to model the design of In-vitro models to account for statistical errors based on the sensitivity 
and accuracy of the assays used by including enough replicates to overcome these limitations and to use 
experts to minimize the risk of bias observations. With a categorical data set, it is often difficult to determine 
whether a correlation exists between the material and variables for cytotoxicity as compared with 
continuous data typically acquired during quantitative tests. This is why it is suggested that qualitative data 
be complemented by quantitative data to detect specific cytotoxic pathways and determine if a correlation 
exists between the material variables and any cytotoxic mechanisms.        
Quantitative assessment of cytotoxicity includes methods that can assess the specific factors related to cell 
or death. One of the most common forms of qualitative assessment of biomaterials in In-vitro models is to 
count the number of viable cells across a material surface (adherence and proliferation) under normal 
incubation conditions. Colorimetric assays are a common qualitative method for assessing the proliferation 
pattern of cells. This method involves the interaction of molecular compounds designed to fluoresce when 
exposed to the cell that change in response to activated cytotoxicity pathways such as specific enzymes, 
cell membrane permeability, cell adherence markers, ATP production, co-enzyme production, and 




viable cells through a hemocytometer or flow cytometer. The light intensity of the fluorochrome density in 
the culture area can be determined using light spectroscopy calibrated to detect the specific fluorescence 
wavelength given off by the fluorochromes or by imaging software (ex: ImageJ) that can determine the 
optical properties of images taken by FM. This is possible only if the fluorochromes remain bound to the 
internal cell structures and minimal leaching out of the cell is observed. One of the most reliable and 
sensitive calorimetry assays in use today are tetrazolium salt-based assays that bind specifically to 
mitochondrial enzyme Nicotinamide adenine dinucleotide phosphate (NADP) which reduces tetrazolium 
salt into a fluorescent protein known as Formazan as an indicator of metabolic activity. Soluble formazan 
present in the surrounding media can then be detected using a spectrometer apparatus where the 
fluorescence intensity can be correlated to give an estimated number of viable cells that is within acceptable 
variations. Each of these assays are labeled as 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) with other iterations often removing the extra step of solubilizing the formazan proteins 
into the media solution (MTS, WST, XTT). 
There are certain compromises that should be considered when choosing specific calorimetry assays. Often 
these assays consist of simple protocols that can be completed with little effort or knowledge in advanced 
laboratory operating procedures while also providing extremely sensitive and accurate data that correlates 
to the physical cell numbers. This presents possible limitations to their effectiveness around different cell 
lineages and any indirect methods of quantifying cell numbers [8, 9]. Some assays could be potentially 
toxic to certain cell lines and some use radioactive isotopes such as [H3] Thymidine. Other indirect assays 
that bind to cellular enzymes and proteins will often not consider other factors that could activate these 
processes besides apoptotic pathways that will often lead to incorrect interpretation of the data [10]. 
Biomaterials can also impact the function of these assays by either activating the fluorescence as a false 
positive or preventing the reagent to bind to its specific target as a false negative. It is therefore essential 
that the limitations of one assay be supported by the advantages of another assay. This will insure that not 
only the data is interpreted correctly but will provide a standard guide for different cell-lines and 
biomaterials of compatible assays that can be utilized In-vitro. 
Other methods involve detecting and quantifying more precise protein/genetic markers indicative of 
activated apoptotic pathways such as pro-apoptotic genes (bax, bak, cytochrome c) and anti-apoptotic genes 
(bcl-2, bcl-xl, Mcl-1). Western blot (WB), quantitative polymerase chain reaction (qPCR), and 
immunofluorescence (IF) are all methods capable of identifying apoptotic pathways initiated by a specific 
toxicity profile. The ratio of labeled surface markers, gene sequences, or proteins to the total image area or 
volume of cell culture can be quantified to indicate whether apoptotic behavior is present along one or more 




1.1.1.2 In-vivo Models 
While In-vitro models are a simpler model designed to control experimental variable interactions to 
determine correlations between them, they are incapable of recreating the same biological/ physiological 
environment that the implant will be exposed in living organism and there for the full spectrum of 
measurements of biomaterial performance cannot be assessed.   In-vivo models are a more complex system 
in which two or more experimental variables including factors not included in the In-vitro model or 
considered relevant are now exposed. Inflammatory responses, degradation, biochemical kinetics, 
angiogenesis, and 3D tissue remodeling are complex processes that can only be fully studied In-vivo. This 
can make opportunities to observe and identify associations between variables difficult. The goal of an In-
vivo model is to not only mimic the physiological conditions of the clinical case but to obtain meaningful 
data that can be measured and analyzed to find clinically relevant differences in material performance. It is 
prudent to observe overall physiological reactions and compare them to the current gold-standard (positive 
control variable) and clinical care to determine the efficacy of the implant towards its intended targeted 
therapy. This is an essential step in the process of evaluating an implant for clinical assessment and therefore 
requires careful selection of the model system and variables to control/access depending on the application 
of the implant and the current standardized guidelines described by both ISO and ASTM protocols for In-
vivo testing.   
The use of mammalian physiological systems can accurately represent most of the conditions that 
biomaterials will be exposed to under practical clinical applications and is therefore currently the best 
method for assessing how biomaterials will perform in a physiological system that is to a degree similar to 
that of a human system. There are variables of In-vivo models that we can tightly control such as anatomical 
location of implant site, size of the implant incision, species, gender, age, sample size, and methodologies 
for assessing material performance in an attempt to standardize animal models. The design of the model 
should narrow and strengthen cause/effect relationships of physiological events to the interaction of 
biomaterials. The controlled variables should also be focused towards answering specific questions related 
to the assessment of biomaterials in one or all domains of In-vivo biomaterial assessments (biocompatibility 
testing, bioactivity testing, or preclinical testing), while having the ability to translate these control 
parameters to more complex or different animal models.  
In-vivo assessment of biomaterials for neural regenerative applications must therefore fall under the same 
system of standardization of In-vivo models. The number of In-vivo studies that have looked at repair of 
peripheral nerves using scaffolds has created a varied list of the most common animal model designs and 
methodologies for assessing nerve recovery in an attempt to standardize such studies. A study from 2012 




that the majority of these studies utilized rat models to assess scaffold performance followed by mouse and 
rabbits respectively. Of these studies, the majority create defects in the sciatic nerve with most defect gaps 
between 5-10 mm. The study also reports that within the studies using rat models the most commonly used 
method to assess nerve healing is through Quantitative Histology analysis, followed by nerve morphometric 
analysis, electrophysiology, and Immunohistology respectively. The number of animal parameters to 
consider and the degree of control between model variables has created problems among investigators in 
establishing a consensus on the best animal model design and methods for assessing nerve recovery.  
 1.1.2 Polymers 
Polymers are a class of biomaterials that has seen an enormous surge in research and in the design of 
medical devices. Research on polymer incorporation in neural scaffold and conduit implant designs is well 
represented in the literature, going back as far as the early 1960s. Studies have shown that many polymers 
are capable of interacting with the native tissue with minimal toxicity. Polymers have a distinct advantage 
over other commonly used biomaterials in dynamic physiological environments in that they can be designed 
to incorporate multiple therapies into their design to further improve tissue regeneration success. Polymers 
can be easily handled and stored at low cost to the manufacture and customer. The methods for synthesizing 
polymers provide a unique opportunity for exploring a diverse range in polymer combinations and 
understanding how these new molecular structures impact their physical, chemical, and biological 
properties. Polymers have also shown an ability to successfully integrate with cells and tissue in In-vitro, 
ex-vivo, and In-vivo models while maintaining minimal inflammatory and foreign body responses over 
extended periods of time. Polymers can be further functionalized to express specific traits that are time 
dependent such as controlled degradation/ inert reactions, drug and protein delivery systems, mechanical 
integrity in response to thermal and mechanical responses. The traits of certain polymers would correspond 
to the definition of a biomaterial. Polymers as biomaterials can be organized into two distinct categories: 
natural and synthetic based polymers.  
1.1.2.1 Natural Polymers 
Natural polymers have a distinct advantage over other biomaterials due to their natural origin from 
physiological systems. Since these polymers are composed of organic molecules that are manufactured by 
physiological processes, they have a higher chance of success when interacting with In-vivo physiological 
systems such as immunomodulation, tissue interaction and reinforcement, and degradation. These polymers 
also are capable under specific physiological conditions to produce these materials in abundance which has 
a manufacturing advantage. There are a variety of natural polymers that are capable of being processed into 




Degradation occurs by both hydrolytic and enzymatic processes. Natural polymers are most often 
compatible with the host extracellular matrix (ECM) which is expected to improve scaffold bio-integration. 
Some of the most common natural polymers investigated for the development of scaffold designs are 
polysaccharides (PSA), and poly amino acid chains (PAAC).  
(PSA) are a family of naturally occurring monosaccharides cross-linked together with glycosidic linkages 
(ether bonds) of both human and non-human origin. The most common examples of these types of materials 
used in biomaterial applications are chitosan, hyaluronic acid, fibrin/fibrinogen, cellulose, alginate/agarose, 
and dextran. These types of polymers are susceptible to biodegradation and are composed of functional 
bioactive sites that have been investigated for applications involving controlled drug release, improved 
cell/tissue interaction by modifying existing scaffold designs, and increased resistance from immune 
response.   
(PAAC) are highly organized collections of either natural or synthetic amino acid chains making them 
mechanically versatile with little risk of activating adverse immune reactions. Some of the most common 
(PAACs) under current investigation are polypeptide chains such as elastin, collagen, and blood proteins 
such as albumin. Similar to PSAs, these constructs are very susceptible to biodegradation through 
hydrolysis and enzymatic degradation.   
1.1.2.2 Synthetic Polymers 
Synthetic polymers have been in great demand as an alternative to natural polymers when designing tissue 
scaffolds. While natural polymers have a higher success of positive bio-interaction with the surrounding 
tissue and are of a lesser risk of inducing toxicity, synthetic polymers have almost unlimited potential for 
synthesizing various forms of biomaterial designs without the need to harvest, sterilize, or decellularized 
native tissue. This makes synthetic polymers a more attractive alternative to natural polymers for creating 
universally compatible and market feasible scaffolds. The simple and cost-effective means of synthesizing 
these polymers and their co-polymer iterations allow for excellent quality control during the manufacture 
phase. Synthetic polymers have many different types of manufacturing and modification processes 
available for conduit designs. This provides opportunities for careful tailoring of biomaterial variables to 
improve polymer structure stability during long storage periods at room temperature and incorporation of 
specific functionality traits that can improve mechanical stability, bioprocessing, and bio-interactions in 
physiological systems. Such examples for manufacturing physical features include electrospinning, mold 
casting, gas or solvent evaporation, sputtering, and printing while surface modifications include covalent 




Synthetic polymers composed of α-ester-based functional groups are the most utilized material for 
designing synthetic polymer scaffolds with controlled biodegradation. These aliphatic polymers are more 
susceptible to hydrolytic, and oxidative degradation due to the hydrophilic regions of the ester groups 
reacting with polar molecules and reactive oxygen species (ROS) resulting in successful scission of ester 
bonds in physiological systems. This will often reduce the polymer chains into α-hydroxy acid monomers 
(ex: lactic acid, glycolic acid, carboxylic acid, hyaluronic acid (HA)) of minimal toxicity and removed 
through renal excretion. Examples of these types of aliphatic ester polymers include poly(lactic acid) 
(PLA), poly (L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), 
poly(ε-caprolactone) (PCL), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), polydioxanone 
(PDS), polyethylene glycol (PEG) and certain forms of polyurethanes composed of ester and carbonate 
groups as isocyanates (poly(ester urethane) (PEU), and poly(carbonate urethane) (PCU)) [11–13]. These 
polymers are often labeled as hydrophilic which describes the ease in which water molecules can react to 
the polarizing regions of the polymer ester-chains. In the presence of oxidative redox reactions these 
hydrophilic regions can become more polarized to be further susceptible to hydrolytic and enzymatic 
degradation. Oxidative reduction may take place in the form of redox reactions usually involving 
hydrocarbon section of polymer chains that are hydrophobic regions. This will involve oxidative species 
such as carbonyl, carboxylic, peroxide, and hydroxyl groups that will actively oxidize the material, thus 
polarizing the material to create hydrophilic regions [14]. Polymer degradation can also occur from 
enzymatic reduction in the form of both hydrolases and oxidoreductase pathways such as depolymerase, 
peroxidase, and mono or di-oxygenase.  
The degree of access to these reactive regions in the polymer chain to enzyme, oxidative groups, and polar 
molecules will result in different polymer absorption profiles as described in Table 1.3 as the most common 
degradation products and rates determined in these polymers. The degradation profile in these polymers are 
subject to scrutiny as the degradation rate can change by a large degree in physiological systems when 
considering dynamic temperature, ph., ROS, enzyme and polymer degradation product concentrations In-
vivo [15,16]. Other forms of biodegradation such as chemical functionalization, light exposure, microbial 
interaction, mechanical stimulus, sterilization techniques, and architectural modifications to the material 
should be considered as they can also have a significant effect on the degradation profile of biodegradable 







Table 1.3 Degradation properties of synthetic biodegradable polymers  
Polymer  Degradation product Degradation period (months) Reference 
PLLA L-lactic acid 6-24 Garlotta, 2001; Zilberman                  
et al., 2005; de Tayrac                  
et al., 2008; Armentano                
et al., 2010                 
PGA Glycolic acid 3-6 Wen and Tresco, 2006; 
Armentano et al., 2010 
PLGA D, L-lactic and                       
glycolic acids 
3-12 Lu et al., 1999, 2000;   
Armentano et al., 2010 
PCL caproic acid 18-36 Nair and Laurencin, 2006;      
Pena et al., 2006 
POE cyclohexane dimethanol   
propionic acid                               
1,6 hexane diol        
pentaerythitol dipropionate    
Pentaerythitol 
6-34 M.S. Tatlor, 1994 
PHBV crotonic acid                          
butyric-2                                     
isopropyl-2 
6-39 Muhamad et al., 2006            
Xiang et al., 2016 
         
PDS glycoxylate                             
glycine 
6-12 Ray et al., 1981 
PEG peroxides                                 
glycolic acid                              
monoalkyl ethers                     
ethylene glycol 
9-18 Guo et al., 2012                        
Webb et al., 2013                     
Andersen et al., 1999 
PEU hyaluronic acid groups               
Urea                                               
Urethane 
N/A Ravi et al., 2009                          
Blais et al., 1990                         
Szycher et al., 1991 
PCU Carboxylic acid groups               
Urea                                               
Urethane 
N/A Ravi et al., 2009                          
Source: M.E. Marti, A.D. Sharma, D.S. Sakaguchi, and S.K. Mallapragada. 2013. “Nanomaterials for Neural Tissue Engineering.” In Nanomaterials 
in Tissue Engineering Fabrication and Applications, edited by A.K. Gaharwar, S.Sant, M.J. Hancock and S.A. Hacking, 275–300. 56. 1518 Walnut 
Street, Suite 1100, Philadelphia, PA: Woodhead Publishing Limited.  













The other category of synthetic polymers is characterized as non-degradable, biostable carbon chains that 
are able to resist hydrolytic, oxidizing, or enzymatic processes due to the stable configurations of the carbon 
bonds and prevention of access to the sensitive polar regions of the polymer structure. This labels these 
polymers as hydrophobic which describes the difficulty in which polar molecules can react to the polarizing 
regions of the polymer chain, resulting in extremely slow or negligible absorption profiles that are often 
characterized as having inert reactions to physiological systems. Such examples include 
Polytetrafluoroethylene (PTFE) with carbon-carbon bonds surrounded by stable fluorine atoms, or poly 
(vinyl alcohol) (PVA) with carbon-carbon bonds surrounded by stable hydroxyl groups. Polyurethanes 
(PU) are most often utilized in inert or biostable medical device applications. By selecting specific polymers 
that can be used as soft segments (polyols) and hard segments (diisocyanates) the creation of biostable 
urethane and block chains can be created with mechanical ratios between stiffness and elasticity. PU can 
be tailored to be more biodegradable by introducing ester-based polyols for the soft segment component 
such as PLA, PGA, or PCL resulting in a variety of different biodegradation profiles.  
These polymers are categorized under FDA regulations as non-degradable polymer substrates that are 
highly resistant to bio-resorption making them overall inert to cell/tissue interactions and highly resistant 
to immunomodulation processes In-vivo. This makes inert polymers excellent for blood or cerebral fluid 
contact, mechanically intensive, or drug delivery applications. However, this presents limitations with 
successful integration with target tissues and the potential for foreign body reactions due to the inability of 
cell/tissues to recognize the material as a native material making long duration use of these materials In-
vivo difficult.       
1.1.3 Nerve Conduits  
The development of neural scaffolds has been researched as a potential solution to improving the quality 
of nerve tissue regeneration over extended regeneration distances. Both natural and synthetic polymer 
scaffolds by themselves still underperform when compared to the current gold standard for PN defects 
greater than 3 cm. To address this challenge, many studies have begun to look at combining multiple TE 
techniques together in polymer scaffold designs such as stem cell support, anisotropy surface architecture, 
and surface coatings to improve the limitations of synthetic scaffolds [18]. The majority of these In-vivo 
studies show a significant improvement in neural repair, with successful bridging of neural defects up to 3 
cm in length being reported. A current gap in neural scaffold development is determining the optimal 
biomaterial design that can facilitate peripheral neuron and Schwann cell adhesion and orientation that is 
biomimetically similar to the surrounding (ECM) but remains structurally stable over long durations of 
implantation. This involves investigating the potential cytotoxic and neuro-regenerative effects with 




The goal of which is to create a material engineered to a specific design that will maximize neuro-
regenerative output in clinical cases. The following section will highlight techniques investigated in the 
design of nerve conduits and the current observations regarding their potential for regenerating peripheral 
nerves compared with the quality expected of the current gold standard (autologous graft). 
Materials investigated for the development of neural conduits have consisted of both natural and synthetic 
materials. Natural materials as structural components in neural scaffold designs have focused primarily 
towards polysaccharides of both human and non-human origin. Currently type 1 collagen and small 
intestinal submucosa-based scaffolds are the only FDA approved natural material nerve scaffolds available. 
Synthetic materials that have currently been explored for potential in neural scaffold designs include 
silicone, ceramics, carbon-based, and polymer materials with few polymers being FDA approval for use in 
clinical applications of severe neuropathies (PVA, PGA, PLCL).  
The vast majority of peripheral nerve scaffolds have designs that are rigid hollowed-out tubes or films 
wrapped into tubular structures of varied lengths and sizes as needed to bridge the defect site. This type of 
design is most effective in bridging the two PN ends across the gap with minimal tension. The concept is 
to fully encapsulate the site of injury for more controlled guidance of nerve healing. Such encapsulation 
provides opportunities for more direct appliance of targeted therapy techniques such as culturing support-
cells to the interior scaffold structure, mechanical and physical ques from tissue interaction with the scaffold 
material, and controlled drug elution/ transport. Over the years, neural scaffolds have undergone extensive 
design changes that now incorporate components that are specifically designed to further stimulate 
controlled nerve growth by careful selection of material properties, geometric and surface features, and the 
ability to integrate with surrounding tissue resulting in higher rates of successful nerve rehabilitation 
outcomes. The current market of FDA approved neural conduits and neural protectants/wraps composed of 











Table 1.4 Most current list of FDA approved neural conduit and wraps designs  
Available FDA approved nerve guide conduit devices 
510K approved FDA clearance date Product name Material Degradation Diameter Length Company   
K983007 22nd March,       
1999/1995     
Neurotube® Polyglycolic acid 
(PGA) 
3 months 2.3-8 mm 2-4 cm Synovis® Micro Companies Alliance 
Inc.,      www.synovismicro.com 
K011168 22nd June, 2001 NeuraGen® Type I collagen 36-48 months 1.5-7 mm 2-3 cm Integra Life Sciences Corp.,   
www.integra-Is.com 
K012814 21st Sept, 2001 Neuroflex™ Type I collagen 4-8 months 2-6 mm 2.5 cm Collagen Matrix Inc., 
www.collagenmatrix.com 
K012814 21st Sept, 2001 NeuroMatrix™ Type I collagen 4-8 months 2-6 mm 2.5 cm Collagen Matrix Inc. 
www.collagenmatrix.com 
K031069 15th May, 2003 AxoGuard™            
Nerve 
Connector 
Porcine small      
intestinal        
submucosa (SIS) 





2003/4th May, 2005 
Neurolac® Poly (DL-lactide-              
ε-caprolactone); 
PCL 
16 months 1.5-10 mm 3 cm Polyganics B.V., ww.polyganics.com 
K100382 5th August, 2010 SaluTunnel™ 
Nerve 
Protector™ 




2-10 mm 6.35 cm Salumedica™ L.C.C., 
www.salumedica.com/ 
Available FDA approved absorbable nerve cuff/protectant wrap devices. 
510K approved FDA clearance date Product name Material Degradation Diameter Length Company   
K002098 24th November,      
2000/2001 




2-10 mm 6.35 cm Salumedica™ L.C.C., 
www.salumedica.com/ 
K031069 15th May, 2003 AxoGuard™ 
Nerve Protector 
Porcine SIS 3 months 2-10 mm 2-4 cm Cook Biotech Products,   
www.cookbiotech.com 
K041620 16th July, 2004 NeuraWrap™ Type I collagen 36-48 months 3-10 mm 2-4 cm Integra Life Sciences Corp., 
www.integra-Is.com 
K060952 14th July, 2006 NeuroMend™ Type I collagen 4-8 months 4-12 mm 2.5-5 cm Collagen Matrix Inc. 
www.collagenmatrix.com 
Source: Kehoe, S., X. F. Zhang, and D. Boyd. 2012. “FDA Approved Guidance Conduits and Wraps for Peripheral Nerve Injury: A Review of  














1.1.3.1 Conduit Designs 
The development and assessment of a variety of neural conduits and wraps has provided the foundation for 
what criteria should be considered when designing such devices to ensure that the device will perform at a 
level that meets or exceeds the clinical standards for acceptable peripheral nerve repair (autographs), while 
minimizing incidences of both mechanical and physiological failure during the course of repair. The current 
design criteria considered to be essential for successful neural conduit and wrap implementation is 
described in Table 1.5 [20]. The majority of peripheral nerve conduit designs both on the market and under 
research investigation conform to a simple hollow cylinder structure. This design resembles the peripheral 
nerve anatomy to its most simple geometric shape making it easy to manufacture with minimal variations 
between completed products depending on the material used (natural or synthetic). Functionally it can fulfill 
the basic requirements expected of a neural conduit or wrap design for repair of critical defects. This 
includes bridging the two ends of the proximal and distal stumps, holding its shape and mechanical stability 
for the duration of nerve growth, allow for permeability of nutrients and waste from the repair site, and 
support neural cell adhesion and guidance. However, the most recent developments in both natural and 
synthetic neural conduits and wraps is that they must also incorporate both mechanical and chemical cues 
into the design to achieve the neural regenerative potential of autographs.  
 
 Table 1.5 Design Criteria for Nerve Wrap and Conduits 
Ideal properties Description 
Biocompatibility Material should not harm the surrounding tissues 
Degradation/ porosity Degradation rate should complement nerve regeneration rate; conduit should 
allow nutrient diffusion and limit scar tissue infiltration 
Anisotropy 
An internal scaffold or film should provide directional guidance  
Protein modification/ release Laminin/fibronectin coating for increased cellular adhesion; controlled/sustained 
growth factor release 
Physical fit Conduit should have a large enough internal diameter to not "squeeze" the 
regenerating nerve; wall thickness limited 
Support cells Schwann cells/stem cells capable of delivering neurotrophic factors to the site of 
regeneration 
Electrically conducting 
Capable of propagating electrical signals 
Source: Nectow, Alexander R., Kacey G. Marra, and David L. Kaplan. 2012. “Biomaterials for the Development of Peripheral Nerve Guidance 






The majority of peripheral nerve conduit designs both on the market and under research investigation 
conform to a simple hollow cylinder structure. This design resembles the peripheral nerve anatomy to its 
most simple geometric shape making it easy to manufacture with minimal variations between completed 
products depending on the material used (natural or synthetic). Functionally it can fulfill the basic 
requirements expected of a neural conduit or wrap design for repair of critical defects. This includes 
bridging the two ends of the proximal and distal stumps, holding its shape and mechanical stability for the 
duration of nerve growth, allow for permeability of nutrients and waste from the repair site, and support 
neural cell adhesion and guidance. However, the most recent developments in both natural and synthetic 
neural conduits and wraps is that they must also incorporate both mechanical and chemical cues into the 
design to achieve the neural regenerative potential of autographs.  
Mechanical modifications to neural conduits have focused primarily on maintaining mechanical stability 
and improving cell adhesion and guidance during nerve regeneration. Micro-scale modifications to date 
have involved internalizing parallel channels, filament, or ECMs that are more similar (biomimetic) to the 
peripheral nerve structure. These can be even further modified with the additions of nano-scale surface 
modifications to change the degree of cell adhesion, cell guidance, diffusion of nutrients and waste through 
the conduit, and degradation rate. Micro-channels and nano-groove pattern surface modifications appear to 
perform the best at adhering and guiding neural and Schwann cells [21]. Multipotent cell-lines such as 
neural and mesenchymal stem cells have also shown improved potential for neural differentiation on these 
types of architectural modifications as well. From a mechanical perspective, modifying the surface to 
increase the diffusion rate across the devices surface such as by creating porous or creating nanofiber or 
ECM meshes will increase the rate of degradation causing the conduit or wrap to fail at an earlier time. 
However, this can be negated by careful selection of the conduit material. 
Chemical modifications are often used to either alter the bulk design of the conduit to attach and release 
organic compounds intended to enhance nerve healing, or surface alterations to improve cell-material 
interactions [22, 23]. Some of the most well-known forms of chemical alterations have been oxidizing or 
PEGylation to material surfaces, or adding nanoparticles designed to resist microbials and improve 
electrical conductance on the material.  Biological modifications involve the attachment of either proteins, 
cell, or protein motifs that can better simulate the physiological conditions needed to enhance nerve 
regeneration. The most common techniques utilized have been to bind specific neurotrophic factors 
necessary for nerve regeneration to take place such as nerve growth factors (NGF), brain-derived 
neurotrophic factors (BDNF), and glial-derived neurotrophic factors (GDNF), or incorporate stem cell 
therapies to enhance nerve regeneration by modulating inflammation, releasing appropriate growth factors, 




   
 
Figure 1.1 Ideal neural conduit design configurations (Physical and Biological cues) 
Source: Gu, Xiaosong, Fei Ding, and David F. Williams. 2014. “Neural Tissue Engineering Options for Peripheral Nerve 











1.2 Peripheral Nervous System 
The Peripheral Nervous System (PNS) is a major component of the nervous system that serves to process 
and transport stimulus signal from peripheral sensory receptors to the Central Nervous System (CNS), and 
then relay the appropriate motor response to all appropriate target tissues remote from the CNS. The PNS 
can be subdivided into sensory nerves (afferent) and motor nerves (efferent). Efferent nerves can be further 
subdivided into autonomic and somatic motor divisions. Autonomic nerves control the motor responses of 
soft tissue components (i.e. soft muscle, cardiac muscle, gland secretion), while somatic nerve components 
are more responsible for skeletal muscle functions. In this work, we focus on the sections of the PNS that 
are distal to the spinal cord where the configuration and organization of the PNS in human models are 
similar and consistent with other mammalian models. All PNS distal to the spinal cord consist of neurons 
bundled together and divided into specific sections known as fascicles, which are wrapped around a thin 
sheet of endoneurium connective tissue composed of elastic and collagen fibers. These fascicles are then 
bundled together by perineurium connective tissue composed of reticular and collagen fibers. The fascicle 
regions combined with the neural blood vessels that support PNS are then held together using the outer 
epineurium connective sheet that tightly compacts the components into the peripheral nerve segment 
(Figure 1.2) [24].  
 
 
Figure 1.2 Peripheral nerve anatomy 
Source: Siemionow, Maria, and Grzegorz Brzezicki. 2009. “Chapter 8: Current Techniques and Concepts in Peripheral Nerve Repair.”  International 





Neurons are the primary cellular units of the PNS responsible for transducing chemical neurotransmitter 
signals into electrical signals that can propagate across the cell body to their intended location and vice 
versa. Dendrites will receive neurotransmitter signals from neighboring cells. This will cause Na+ channels 
on the cell body to open, causing a graded potential to occur across the cell membrane at the region where 
the cell body integrates with the axon known as the axon hillock. If the summation of potential difference 
is great enough to succumb the potential threshold, the Na+ channels on the axon membrane will depolarize 
to allow in-flow of Na+ ions into the axon. Afterwards, the axon membrane will depolarize by out-flow of 
K+ ions. This ion channel exchange will insure propagation of the membrane potential difference across the 
axon membrane until it reaches the synapse site at the opposite end of the axon. Membrane potential will 
then excrete the appropriate neurotransmitter that will bind to the post-synapse of the adjoining neuron thus 
continuing neuron communication thru both chemical and electrical synapses thru the physiological system 
until the signal reaches its intended target synapse.  
The other primary cellular component of the PNS are the Schwann cells, whose primary role is to unsheathe 
the neurons and provide neurotrophic factors essential for neuron survival and regeneration. Most Schwann 
cells will layer themselves across the neural axon segments as a myelin sheath, ensuring that ionic potentials 
are guided and have fast conductance across the axons. non-myelinated Schwann cells are primarily used 
for production of neurotrophic factors necessary to maintain normal PNS functions, and repair of damaged 
nerves. The last cellular component are the stromal connective tissues that isolates the axons from the ECM 
and mechanically support the length of the axons. This is divided into three subsections of connective 
tissues as previously discussed (endoneurium, perineurium, and epineurium). During PNS repair, other 
connective tissues like fibrinogen and laminin will support Schwann cells during the reinnervation of the 
damaged nerve section (Bands of Bungner).      
1.2.1 Peripheral Neuropathies   
Peripheral neuropathy (PN) is a condition of the peripheral nervous system that currently affects over 20 
million US citizens, with a prevalence of 3% in all trauma patients showing some form of PN. Most forms 
of PN can be attributed to mechanical, thermal, or infection damage. PN will often present itself with either 
swelling that blocks the neural conduction (neuropraxia), disruption of the axon or myelin sheath due to 
stretching or crushing stressor (axonotmesis), or tearing or complete separation of the nerve section 
(neurotmesis). The Sunderland Nerve Injury Classification Scheme (SNICS) is the most commonly used 
method for clinical evaluation of the severity of peripheral nerve injuries after physical traumas is induced. 
neurotmesis is the most severe type of peripheral injury where the nerve segment is completely transected 
cutting off the action potential to all sensory and motor functions. Often classified as a type 4 or 5 on the 




Table 1.6 Nerve Injury Classification 
Sunderland Seddon Features 
Type 1 Neuropraxia Damage to the local myelin only 
Type 2 Axonotmesis Division of intraneural axons only 
Type 3 Axonotmesis Division of axons and endoneurium 
Type 4 Axonotmesis Division of axons endo and perineurium 
Type 5 Neurotmesis Complete division of all elements including epineurium 
Type 6 Mixed Combination of types 2-4   
Source: Grinsell D, Keating CP. Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies. Biomed Res Int.  
2014;2014: 698256 
 
Patients with neurotmesis will often experience symptoms of both acute and chronic motor and abnormal 
sensory sensations that overall diminish the quality of life for people [29]. Almost all neurotmesis injuries 
require surgical intervention to insure the nerve heals properly to regain its functionality. Severe 
neurotmesis involves significant gaps (>2 to 3 cm) that require surgical placement of neural grafts to serve 
guidance of axons as they grow across the gap [30].  
Currently, the gold standard for repair of severe neurotmesis is the use of nerve segments taken from the 
patients (autografts) [25, 31]. However, this method is limited in the degree of healing possible at the 
damage site [32]. Surgical protocols require precise matching and orientation of the graft at the two ends 
of the gap which is difficult and requires skilled microsurgery. The suturing of the graft can rupture or 
pierce the perineurium around the fascicles, causing scar tissue to form which can cause further problems 
at the site as iatrogenic peripheral neuropathy. The outcome of this strategy usually involves the following 
implications: donor-site morbidity, sensory loss, scarring at the donor site, neuroma formation, pain, and in 
the case of allografts long periods of host immunosuppression [27, 33]. The low quality of recovery for 
neurotmesis cases results in patients affected by chronic peripheral neuropathy symptoms. This contributes 
to an overall decrease in the wellbeing of the population and an increase in the health care costs utilized for 
repair and management of these symptoms. Currently, healthcare costs associated with PN injuries is 
estimated at around $150 billion annually. This presents a stressing need to research new alternative 






1.2.2 Endogenous Nerve Repair 
If the nerve segment sustains 20-30% of axon damage then collateral branching will most likely be the 
primary mechanism of recovery, however if over 90 % of the axons are damaged then axonal regeneration 
will be the most likely mechanism of repair [25]. The Wallerian degeneration process begins approximately 
24-48 hours post time of injury and will last for a week depending on how severe the injury is. During this 
time, Schwann cells will begin to express pro-inflammatory and neurotrophic factors that will increase 
macrophage intrusion to the site and stimulate surrounding Schwann cells to further activate appropriate 
neurotrophic growth factors or to differentiate prolific Schwann cells to remove cellular debris and break 
down the nerve segment at both proximal and distal ends until the closest stable neuron body is reached in 
a process known as Wallerian- degeneration [34]. The result is a proximal and distal nerve stump created 
by granulation of Schwann cells that concludes the Wallerian degeneration step. The next step is axonal 
regeneration which first breaks down the nerve stumps thru a form of apoptosis which sees a large uptake 
in Ca+2.  At the same time, non-myelinating Schwann cells will migrate and orient themselves on laminin 
and fibronectin chains with the endoneurial tubes at the distal end to create a tubular banded structure known 
as the bands of Bungner. These non-myelinating Schwann cells continue to promote axon regeneration by 
secreting neurotrophic factors that will promote growth cone formation, filapodia probing, and stimulate 
pro-myelinating Schwann cells to orient themselves into myelin sheaths. This will continue until the 
regenerating axon growth cone reaches and assembles with the distal nerve section for complete 
reinnervation to take place. (Figure 1.3) [35]. 
 
 
Figure 1.3 Endogenous peripheral nerve regenerative process 





The chance for successful reinnervation to take place with this form of nerve healing is depended on the 
severity of the injury itself. We can determine this by assessing if the endoneurial tubes are intact, the length 
of the defect, and the presence of lesion or scar tissue. In the case of neurotmesis injuries with critical size 
defects the chances of successful reinnervation are practically impossible without surgical intervention. The 
difficulty is being able to maintain a stable Band of Bunger structure which becomes much less stable as 
the defect size increases. This makes it difficult to guide axonal growth and often it will lead to loss of 
nerve functionality due to scar tissue formation and misalignment of axon bundles to the appropriate distal 
axon bundles. Another issue to consider is the amount of time it will take for full reinnervation to be 
complete for end organ functions to return. While some sensory neuron end-plates can last for many years 
before succumbing to atrophy, motor neuron end-plates begin to undergo atrophy in 3 weeks post injury 
and can last for up to a year before irreversible damage to the endplate incurs leading to complete loss of 
muscle function. The need to create stable neural scaffolds for prolonged stability and axon guidance is 
therefore apparent in order answer these limitations that are apparent in endogenous repair of critical neural 
defects. 
1.3 Graphene 
Graphene in its pristine form (PG) is a continuous SP2 Hybridized carbon film one atom thick, with carbon 
atoms organized in a hexagonal lattice configuration that resembles a honeycomb structure. The carbon 
atoms lateral to each other are held together by both single and double covalent bonds, while all atomic 
bonds perpendicular to the film are weak Van Der Waals forces. The configuration of the carbon atoms 
gives the material a unique conductance, mechanical, and bonding profile when combined with organic-
based compounds that rivals other competing materials. The usage of Graphene Family Nanomaterials 
GFN’s has been used primarily as an additional component to improve the mechanical, thermal, and 
electrical conductance of medical devices used in research. However, GFN’s have been discussed to have 
potential in cell integration and differentiation of numerous cell lines much of which has not been fully 
understood to date. This has naturally led to the discussions of whether GFNs might have potential as a 
conduit platform to assist in the regeneration of damaged tissue In-vivo. Research to date would indicate 
that GFNs can be constituted as a biomaterial that in both In-vitro and In-vivo assessments has shown to be 
capable of supporting positive tissue regeneration for a variety of different tissue phenotypes while retaining 
acceptable biocompatibility traits over extended periods of time. This section discusses the current findings 
for carbon–based materials as a potential biomaterial option and its potential as a component in the design 





1.3.1 Graphene Biocompatibility   
Carbon based materials have been investigated as a component for implanted medical therapies for more 
than half a century, and in this time have resulted in our further understanding of the properties of carbon 
and how they interact with carbon atoms and organic compounds resulting in the prodigious development 
of different carbon-based biomaterials to date. In-vitro studies on GFN coated substrates have consistently 
shown evidence to support that GFNs can act as a bioactive surface coating that can support the adhesion 
and maturity of a variety of cell-lines, including pluripotent cell-lines. In this section we will focus on the 
primary evidence to support GFN biocompatibility involving its potential for stable adhesion of cell lines, 
and its niche properties for controlled differentiation of pluripotent cells.   
1.3.1.1 Adhesion  
Adhesion of cells to a biomaterial surface is a critical event needed for successful application of biomaterial 
therapies. Successful adhesion of cells to any biomaterial surface can be characterized as the integration of 
a cell to the extracellular matrix, bioactive surface, or neighboring cells present on the material surface. 
This is essential for cells to stimulate a positive regenerative environment by regulating correct cell 
communication, mobility, differentiation and stability. Previous In-vitro studies have assessed the surface 
characteristic of different GFN’s and have found that they are capable of absorbing cells lines of both 
immortal and multipotent cell lines in the form of electrostatic attraction, integrin binding, and focal 
adhesion binding pathways. The degree of adhesion varies based on the surface characteristics of GFN such 
as particle size, topographic features, geometric configuration, surface potential, and molecular bonding 
sites of the GFN surface. GFN surfaces can be modified for specific protein and cell adhesion profiles in a 
number of ways depending on the intended function of the device. Such alterations create additional protein 
anchors and changes to the biomaterial zeta potential that are most ideal for cell adhesion and ECM proteins 
absorption. In-vitro cell adhesion studies involving graphene oxide (GO) coated films have shown the 
potential for absorption of adhesion-specific proteins on the surface of biomaterials when placed in plasma 
and serum conditions. One study reported In-vitro to yield 25% protein absorption from a specified volume 
of serum on GO surface coated films compared to 8% absorption on Pristine Graphene coated surface films 
of similar surface area. The majority of these studies have found that exposing GFN’s of different iterations 
to different protein solutions will create different protein absorption profiles allowing for the design of 
specific biomaterial protein coronas that can potentially improve the adhesion, communication, and 






Studies have also found that GFN’s has the potential to minimize the adhesion of specific cells that could 
potentially impact the speed and quality of tissue regenerated. As noted in the previous paragraph, non-
adhesion of specific cell lines can also be tailored by altering the surface properties of GFN materials. Thru 
surface modifications, GFN surfaces can minimize the adhesion of microbials, granulation and fibrous 
tissue, platelets, and lymphocytes specific to foreign body reactions. Studies have found that modifying the 
surface of GFN’s have improved antibacterial resistance by modifying the surface with antibacterial 
nanoparticles or altering the lateral dimensions and surface area of carbon-films. Common nanoparticle 
modifications to Graphene surfaces include Silver (Ag) Gold (Au) Titanium oxide (TiO) and zinc oxide 
(ZnO), while Graphene films of higher surface areas have less toxicity towards microbials compared to 
films with lower surface area[36–38]. Chemical modifications such as PEGylation or oxidation have been 
shown to decrease the proliferation of macrophages and lymphocytes, giving GFN’s the ability to minimize 
foreign body reactions.  
1.3.1.2 Differentiation  
Both In-vitro and In-vivo studies have consistently shown that GFN’s have the ability to not only support 
multipotent cell lines conducive to improved tissue healing but also induce these cell lines towards specific 
differentiation phenotypes simply by integrating with the material surface or internalization of the material 
into the cell. Interest has been focused primarily on the ability of GFN’s to differentiate cells with 
multipotency potential (progenitor cells). While the specific pathways and cellular processes involved with 
differentiation of stem cell integration with GFN are still misunderstood, the most current research into 
GFN have been able to narrow down certain stem cell niches most likely responsible for differentiation 
towards specific lineages, giving researches an idea of what pathways and cellular processes to further 
investigate. 
GFN surface properties have been found to be a key component in guiding differentiation of specific 
phenotypes in stem cells. This involves not only the interaction of stem cells with the biochemical properties 
of the material (cell-cell, ECM mesh, surface proteins) but also the physical features such as surface 
stiffness, topography, surface patterning, and orientation[39,40]. It has been established in previous In-vitro 
studies that biomaterials with surfaces of higher modulus (greater stiffness) have a higher capacity for 
osteogenesis in cells of mesoderm origin while surfaces of lower modulus have a higher capacity for 
neurogenesis in cells of ectoderm origin. This is most likely regulated by specific integrin and focal 
adhesion kinase (FAK) mechanotransduction pathways designed to differentiate between mechanical 
stresses brought on by cell interaction with the surface. The addition of GFN as a surface coating will often 
modify the surface to be stiffer which has resulted in a higher density of mesoderm origin cells to 




that specific surface patterns can not only initiate cytoskeletal remodeling but are also important in guiding 
differentiation of cells towards specific lineages through specific mechanotransduction pathways 
(anisotropy)[39]. Studies have shown how PG coatings patterned in parallel line patterns can initiate 
osteogenesis in hMSCs, while surfaces coated with GO in a grid pattern array are able to stimulate a higher 
yield of hMSCs to differentiate towards neural-like lineages than without said pattern. This is further 
supported by studies that have shown ectoderm origin cell lines to differentiate towards neural lineages 
when adhered to GFN surfaces.  
Chemical stimulation by GFNs to guide specific differentiation in multipotent cell-lines has been 
investigated with clear indications that different GFNs exposed to different multipotent cell-lines will result 
in different neural phenotype outcomes. Many of these studies have found that when neural stem cells 
(NSC) are exposed to simple GO or rGO films that they will naturally differentiate towards glial derived 
tissue, while PG and carbon nanotubes (CNT) do not elicit any neural potential at all. However, when GO 
or rGO films are exposed to embryonic stem cells (ESC) they differentiate towards neuron derived tissue 
instead. There is a clear need to further study these interactions as we do not yet fully understand the exact 
stimulant or pathways responsible for neural differentiation in these multipotent cell-lines. It is also not 
clear as to how other factors involved in peripheral nerve repair will impact the differentiation of 
multipotent cell-lines In-vivo (Co-seeding multipotent cell-lines with Schwann cells and macrophages, 
presence of proinflammatory and growth factor compounds, etc.). 
While guidance of neural differentiation can be controlled to some degree by adding GFN’s it is still 
difficult to determine what pathways are being regulated by the material and whether or not complete 
differentiation has occurred, and if so, identifying what phenotype the cell has differentiated towards. In 
most cases, the material will only achieve partial differentiation in the cells, resulting in only a few of the 
traits required to ID a particular neural phenotype to express. These cells are often labeled as neural-like 
cells instead and thus we cannot expect them to provide the same form of repair expected of true neural 
cells. The best indications for the type of chemical stimulus that GFN’s will induce in multipotent cells is 
from the results indicated in toxicity studies. Toxicity studies have consistently found that GFN’s can 
support multipotent cell-line growth and mobility that is essential for neuron and glial transport and 
spreading. It is also known that certain GFNs will induce oxidative stress due to interference of normal 
metabolic activities that will then activate inflammatory and apoptotic pathways. These pathways have been 
found to also be present during endogenous repair of peripheral nerves, particularly when digesting, 
guiding, and differentiating Schwann cells during the early phases of repair [41].  If GFN’s can stress cells 




potentially further stimulate neuron and Schwann cells towards regenerative behaviors or guide multipotent 
cells towards a specific neural-like phenotypes.  
The biocompatibility of GFNs towards different cell lines and the potential to co-functionalize with other 
therapeutic techniques has created interest in incorporating it as a structural component or surface coating 
in 3D neural conduit designs. The toxicity of Graphene in physiological systems is still under investigation 
due to the current literature that supports the presence of cytotoxic behaviors and varying bio distributions 
of different graphene iterations in specific biological environments. It is also clear that there is still 
insufficient data to make conclusions on the cellular mechanisms related to cytotoxicity when graphene 
interacts with native cells. Current toxicity studies have identified specific properties of graphene-based 
materials that are most responsible for influencing toxicity in both In-vitro and In-vivo systems. 
1.3.1.3 Concentration 
Numerous studies have shown that GFN have a dosage-dependent toxicity effect. The concentration of 
GFN attached to the cell membrane and/or taken up by the cell through endocytosis is correlated to 
increased cellular stress causing activation of specific Apoptosis/Necrosis, and inflammatory cellular 
pathways. Similar studies have also looked at different aspects of cell stress with respect to GFN 
concentrations, such as metabolic stressors, genotoxicity, and cell membrane disruption.  In-vitro studies 
that looked at varied concentrations of different GFN iterations have found that cell viability will decrease 
as concentrations of GFN increase. The concentration of GFN particles needed to observe cell death varies 
based on the format and size of GFN particles, functionalization/chemical preparation, and the cell 
phenotype tested. Another degree of variability to consider is that certain cell stressors will be more 
profound based on the GNF type and concentration tested. Studies have shown how Reduced-Graphene 
Oxide (rGO) iterations of the same size and format showed no significant production of metabolic stressor 
metabolites in human umbilical vein endothelial cells (HUVEC) at 10µg/ml concentration but did show 
significant cell membrane disruption at the same concentration [42]. However, current studies indicate that 
regardless of the graphene tested there appears to be a Graphene iteration concentration threshold for every 
cell line that is detrimental to the cell’s health.    
 In-vivo studies are difficult in assessing the dosage-dependency toxicity of GFN at injury sites due to the 
absorption rate of GFN’s and the conduit platforms they are bound to, and the difficulty of tracking GFN 
in real-time. This however, is suitable for assessing the migration and stimulation of GFN towards acute 
and chronic toxicity over specific tissues/organs for extended periods of time. In-vivo studies have looked 
at GFN concentrations present in large tissue/organs and excretions over extended periods of time. One 




graphene compounds located at the lungs, liver, and kidneys at 30 days [43]. The PI’s observed lung 
granuloma formations and intense inflammation in the kidneys indicating difficulty in cleansing the system 
of graphene residuals, thus leading to chronic toxicity resulting in almost 50% of subjects to die. All lower 
GO concentrations tested showed no clinical toxic symptoms with no mortalities in any of the mice subjects 
over a 30-day period. The study did not indicate any blood toxicity or the ability of graphene to bypass the 
blood-brain barrier after tail vein injection in any of the graphene concentrations during the duration of the 
study. This most likely could be attributed to the size of the graphene films, which could not pass the blood-
brain barrier or the nuclear membrane of most cells. This would indicate that the lateral dimension of these 
films is between 100 – 40 nm which is sufficient to passively bypass the cellular membrane.  
The conclusion is that there is still no consensus on the GFN dosage required to elicit toxic effects in In-
vitro or In-vivo. When we factor in size, conformity, and functionalization we create different GFN 
iterations that elicit their own degree of toxicity as the dosage increases. The lack of a standard operating 
procedure for preparing, storing, and validating different GFN iteration concentrations makes supporting 
or contradicting studies of similar aims more difficult as the current literature shows. These problems are 
mirrored when dosages used in In-vitro studies are translated to estimated dosages for In-vivo models. Most 
researchers agree that as the concentration of GFNs increases (regardless of the iteration) a threshold for 
toxicity is reached that will result in declining cell viability In-vitro and chronic inflammation and scar 
tissue formation apparent in lungs, liver, and kidneys In-vivo. Studies focused on assessing 
immunomodulation, genotoxicity, and blood compatibility have also noted this dosage trend which makes 
standardizing studies that use carbon-based materials a primary concern for finding safe dosages.  
1.3.1.4 Size/Morphology 
Graphene can conform to a multitude of different formats and sizes, many of which have been studied in 
physiological systems. There is consensus that the size and type of graphene has a profound effect on the 
toxicity of GFN. The dimensions of GFN have been found to be most important in facilitating whether 
films of a certain size can be internalized into the cell, while the morphology of GFN is found to be more 
responsible in the amount of stress that is induced inside the cells [44]. Studies have found that graphene 
films of large lateral dimensions and surface area show a greater degree of plasma-membrane adhesion due 
to a greater concentration of bonding sites for electrostatic and ECM protein bonding. Such large 
dimensional films are capable of bypassing the plasma membrane by disrupting the membrane integrity by 
puncturing through at the asperities sites on GFN films. Such disruption of the plasma membrane could 
potentially disrupt membrane and cytoskeleton associated proteins for maintaining membrane integrity, 
such as Actg2, Myosin, Tubb2a, and Nebulin. Studies have shown that GFNs deposited on the cell 




like receptors (TLR) and transforming growth factor beta (TGFβ) surface receptors for pro-inflammatory 
and apoptotic induction.  
Graphene samples of smaller lateral dimensions can be taken up much more easily into the cell by diffusion, 
and passive, or active mechanisms (endocytosis, ionic channel pumps, pinocytosis, and phagocytosis). As 
the lateral dimension of graphene films decreases, we begin to see increased uptake into the cell’s cytoplasm 
where subsequent pathways for production of metabolic stressors, and inflammatory cytokines become 
more active. Even smaller graphene particle sizes have the potential to bypass the nuclear membrane, 
resulting in genotoxicity. GFN films with sizes between 100 – 40 nm lateral dimensions are capable of 
passively bypassing the cellular membrane, while GFN films of 40-35 nm lateral dimensions can passively 
bypass the nuclear membrane. All other GFN films smaller than 35 nm are capable of bypassing the blood 
brain barrier. This behavior in cells can relate to how certain sizes of graphene are more prone to elicit 
certain cellular responses that are indicative of cytotoxicity. 
1.3.1.5 Surface Charge/Physiochemistry 
PG and its different forms have a hydrophobic surface due to the covalent bonding of carbon atoms that 
present few areas on the surface for hydrogen atoms and other polar based molecules to interact with 
graphene. When organic compounds covalently or electrostatically bind to a material’s surface that adds or 
changes the surface properties, we refer this chemical modification as functionalization. GFN’s can have 
their surfaces modified in this way to create hydrophilic surfaces more capable of cell adhesion and 
interacting with physiological molecules. The most common examples of this are PG films functionalized 
with oxygen-based groups like hydroxyl (OH-), carboxylic (COOH-), and carbonyl (CO) groups to create 
modified GFN’s like GO and rGO. These groups are usually created thru Hummer’s method that can 
exfoliate the ends of the graphene films using powerful acids like sulfuric or nitric acid to bind to an 
oxidizing reagent such as potassium permanganate. The presence of these oxidative groups changes the 
charge density and zeta potential of the graphene surface making it negatively charged and more susceptible 
to reactions with other polar molecules and making the surface more hydrophilic. This creates a platform 
well suited for cell-adhesion molecules (CAM) to adsorb to the surface. Graphene films highly saturated 
with (CAMs) have a greater success of establishing integrin binding on the surface of cells for controlled 
adhesion and migration. These functional groups can also act as anchor points for attaching polar proteins, 
lipids, antibodies and drug components as a drug delivery platform for targeted or systemic control over 
physiological systems to improve tissue regeneration outcomes. However, preparation of certain functional 
groups could also potentially modify the toxicity of GFNs to make them more toxic to cell lines from both 
an In-vivo and In-vitro perspective. Great care should be taken to ensure that these types of modifications 




observed to increase oxidative stress due to its high concentration of bound oxygen species, or the toxicity 
attributed to impurities created during surface modifications.    
In-vitro studies used to evaluate cytotoxicity of GFNs in immortalized cell lines have found that PG films 
are more likely to localize on cell membranes rather than internalize into the cell due to the strong 
electrostatic attraction of the hydrophobic graphene surface to the negatively charged phospholipid cell 
membrane. It is here that films of large lateral dimensions could interfere with normal cell functions by 
overlapping cell surface binding sites, which can initiate toxicity pathways by preventing cell nutrients and 
waste processes, increase intracellular reactive oxygen species (ROS) concentrations, or immobilizing the 
cell. GFNs can also activate pro-inflammatory receptors such as Tumor Necrosis Factor (TNF), Toll-Like 
Receptors (TLR), and Transformation Growth Factor-Beta (TGF-β). These receptors will follow pro-
inflammatory and apoptotic pathways such as nuclear factor kappa B (NFKB), extracellular signal–
regulated kinases (ERK), mitogen-activated protein kinase (MAPK), and Caspase-3. These pathways will 
often secrete pro-inflammatory cytokines such as Interlukin-1,6,12 (IL-1,6,12), Tumor Necrosis Factor-
alpha (TNF-α), monocyte chemoattractant protein 1 (MCP-1), and Interferon gamma (IFN-g) that will 
further cell death. PG films of smaller dimension and size are more capable of internalizing into the cell 
cytoplasm thru endocytosis and phagocytosis (Figure 1.4: A, B)[45].  
In-vitro studies have consistently reported that high concentrations of GFNs internalized into the cell bodies 
will increase ROS radicals as a result of GFNs interacting with cellular mitochondrial processes. This 
increase in intracellular ROS levels will often activate apoptotic and pro-inflammatory pathways in the 
form of oxidative stress that will eventually lead to cell death if the stress is prolonged. The tricarboxylic 
acid (TCA) or “Krebs cycle” is a component of aerobic metabolic processing in mitochondria necessary to 
store chemical energy in the form of ATP from reduced proteins, fat, lipid, and carbohydrates in all 
eukaryote cells. It has been suggested that GFNs could act as an electron donor that could add electrons to 
redox enzymes at specific points during the Krebs cycle. This form of interference is more likely to occur 
with redox co-enzymes such as nicotinamide adenine dinucleotide (NAD) that can accept electrons from 
hydrophilic (GFN) surfaces. A byproduct of redox reactions is ROS which are the primary source for 
intracellular oxidative stress and at critical concentrations will activate pro-inflammatory, apoptotic, 
necrotic, and autophagy pathways. Other studies have looked at indirect forms of detecting increases in 
ROS such as detecting dynamic changes in lactate dehydrogenase (LDH) enzyme secretions as a direct 





These studies have also reported that the degree of metabolic stressors released internally is dose, size, and 
conformation dependent. Surface area, degree of functional group saturation, and the orientation of 
functional groups on GFN surfaces will also affect the amount of internal metabolic stressors produced 
(Figure 1.4) [45]. In the case of GO or rGO, In-vitro reports indicate a greater degree of metabolic 
disruption compared to pristine graphene iterations due to the presence of oxidative radicals on the materials 
surface. These radicals and the impact that it has on normal mitochondrial processing can increase the 
number of ROS in the cytoplasm which presents a greater severity of toxicity due to ROS reactions with 
cellular components such as protein synthesis, tubulin structure, and mitochondria/nuclear membrane 
integrity. These changes not only disrupt cell function but also induce genotoxicity or epigenetic damage.  
 
 
Figure 1.4 Intracellular toxicity pathways induced by GFNs  
Note: (A) TLR4,9 pathway activation by GFN’s resulting in upregulation pro-inflammatory factors. (B) MAPKs, TGF-beta and TNF-α dependent 
pathways involved in activation of apoptotic factors caspase3 and necrosis caused by GFN’s. (C) Passive transport of GFNs across cell membrane 
with subsequent ROS, LDH, and MDA generation. 
Source: Ou L, Song B, Liang H, Liu J, Feng X, Deng B, et al. Toxicity of graphene-family nanoparticles: a general review of the origins and 











1.3.2 Graphene Neural Conduit Designs 
Based on the current consensus on GFN biocompatibility/toxicity and the pursuit to design neural conduits 
that can address the current debilitation brought about by severe cases of peripheral neuropathies, GFNs 
have been introduced as a material component that could potentially improve current neural scaffold 
functionality [46]. GFNs have been used in the design of neural scaffolds primarily to improve upon the 
mechanical integrity, neural conduction dynamics, and thermal stability of polymer based neural scaffolds. 
However, over the last decade there has been a growing interest to understand how this material can 
integrate with the ECM and cells used in neural regenerative applications and whether as a biomaterial by 
itself can stimulate endogenous neural repair. This has furthered our understanding of GFN as an attractive 
candidate as the primary component in neural scaffolds devices resulting in a variety of GFN neural 
scaffolds designs. The inclusion of GFNs into previous neural scaffold designs have shown improvement 
in nerve conduit and wrap performance by enhancing the devices in regards to the specific design criterions 
previously discussed (Sec 1.1.3.1). 
One of the most studied and often utilized GFN iteration used for improving the performance of nerve 
conduit and wrap designs is GO or rGO substrates (graphenes oxidized with oxidative groups). As 
previously discussed, GO and rGO coated surfaces can not only support neuronal and multipotent cell-lines 
but can direct multipotent cells towards specific neuronal lineages, where as other GFN iterations are not 
as effective or have no effect in directing neurogenesis.  It is for this reason that these GFN’s are often used 
to modify the surfaces of these types of constructs, specifically those surfaces in direct contact to the nerve 
under repair [47]. Apart from the proven benefit of being able to support neural and stem cell therapies, 
these modifications will alter the physical and chemical properties of the construct surface in a variety of 
expected ways that are further advantageous to nerve repair. This includes surface stiffness increase, 
neurogenic anisotropic properties, slightly higher hydrophilic surface charge, electrical conductance 
potential, and further tailored functionality for absorption of neurogenic positive compounds. This makes 
GO, and rGO excellent contenders as surface coatings for enhanced nerve conduit and wrap performance. 
Despite these neurogenic positive properties of GFN, a nerve conduit capable of meeting or surpassing the 
degree of repair achieved by autologous scaffolds has not yet been achieved. Implications involving the 
potential toxicity of GFN’s and the misinformation regarding what pathways are activated or negated when 
multipotent and neuronal cells are exposed to GFN’s In-vivo has created uncertainty as to the materials 
ability to meet the clinical standards for successful nerve repair and whether it will produce adverse effects 
in a clinical setting. This is why to date, there is currently no clinical peripheral nerve conduit or wrap 




1.4 Stem Cell Therapy 
Stem cells are a family of cells that are specifically characterized as undifferentiated cell lines capable of 
self-renewal over long periods of time until exposed to specific environmental conditions that will induce 
the cells towards specialized cell lineages. A common hierarchy of stem cells, starting with the most potent 
stem cell form is to start with totipotent stem cells. These cells are usually present during the early stages 
of embryonic development. Such examples include spores or zygotes, which are capable of differentiating 
into any tissue type possible in the body. After successful fertilization, a culture of these totipotent cells is 
created which will then differentiate into pluripotent cells. Differentiation potential of these cells is limited 
to any three germ layers, these being endoderm, ectoderm, and mesoderm lineages. Endoderm 
differentiation includes lung and gastrointestinal tissue. Ectoderm differentiation includes epidermal and 
neural system tissues. Mesoderm differentiation includes muscle, bone, and blood tissues. Once pluripotent 
cell begins to differentiate towards either of these three pathways, they will further differentiate towards 
progenitor cells that have the potential to differentiate towards multiple discrete cell types, further 
characterized as multipotent cells. An example of this concept are multipotent cells that develop from a 
mesodermal origin that will differentiate towards bone, chondrocyte, or adipose tissue often referred to as 
mesenchymal stem cells (MSC).    
When isolated from adult tissues, multipotent cells have the potential to improve the outcome of tissue 
healing when directly applied to the site of injury or when pre-differentiated towards its intended cell type 
before being applied.  Recent studies have directed interest towards incorporating multipotent cell lines into 
the design of scaffolds to improve regeneration, tissue quality, and cell-material interaction [48]. The scope 
of these types of studies has focused primarily on answering the question of which type of multipotent cell 
line should be used, what form of stimulation is most effective in differentiating cells to express the intended 
therapy, the time and duration of administration In-vivo, survivability, and tracking of the cells In-vivo. 
Investigations using multipotent cell lines for improved neural tissue healing has shown promising results 
in both In-vitro and In-vivo models, particularly when used in collaboration with nerve scaffolds that can 
act as a platform for stable cell growth, cell protection, and elicit its own biomaterial cues to guide cell 
differentiation. The most commonly investigated multipotent cell lines for nerve healing applications have 
been embryonic stem cells (ESC), induced pluripotent stem cells (IPSC), and adult somatic stem cells 
(ASSC). Although ESC and IPSC have shown potential for nerve tissue healing, there are concerns from a 
clinical standpoint due to greater cellular sensitivity towards immunological processes, ethical implications 
involved in using these cell lines, and the technical difficulty in isolating these cells. This makes the use of 




have already been investigated for their potential in nerve repair including ones of both mesoderm and 
ectoderm origins. There is a greater consensus towards using ASSC of mesoderm origin due to its 
prevalence in certain tissue locations and the ease of accessibility to those locations as compared to 
ectoderm origin cell-lines. Although this origin cell-line best represents the tissue being regenerated at the 
site of injury, they are very difficult to isolate making them non-feasible to use from a clinical standpoint. 
Neural crest stem cells (NCSC) and MSC are multipotent cell lines of mesoderm origins that have received 
interest in nerve repair. Their ease of accessibility, simple isolation techniques, and current results have 
shown potential to express cellular structure and behaviors similar to that of ectoderm origin cell lines but 
not exact in every aspect which is termed by many researchers as neuron-like cells.   
1.4.1 Mesenchymal Stem Cells 
MSC are a type of multipotent progenitor cell line that is capable of self-renewal and differentiating into 
specific cells of a mesoderm lineage such as chondrocytes, osteoblast, and adipocytes [49–51]. A type of 
non-hematopoietic adult stem cell line, MSCs are produced in both fetal and adult tissues in most mammal 
species to assist in the repair and maintenance of specific tissues of mesoderm origin such as cartilage, 
bone, fat, skeletal muscle, and tendon. MSCs have been isolated from a variety of fetal and adult tissues 
with bone marrow, adipose tissue, and umbilical cord blood, and Warton’s jelly being the most common 
source due to their high MSC content. The most common natural reservoirs used for collecting MSCs from 
a clinical standpoint are cells derived from bone-marrow or adipose tissue. While both forms of these 
multipotent cell lines have been used to repair nerve with mixed results to date, there are specific advantages 
observed that puts preference of using one form over the other for nerve repair.  
From a clinical stand point adipose tissue is more readily available, adipose tissue is easier to remove, and 
it is easier to isolate MSCs from adipose tissue compared to bone-marrow tissue. This makes adipose 
derived stem cells (ADSC) a more attractive multipotent cell choice compared to bone marrow derived 
cells (BDSC). Furthermore, once ADSCs are isolated from adipose tissue the yield of healthy ADSC is 
much greater and can survive for longer lengths In-vitro than BDSC isolated from bone-marrow tissue. 
From a therapeutic stand point both cell types have immunogenic properties and have shown to expressing 
neural and glial cell markers such as S100B, GFAP, P75, and Tuj-1 and are able to release neurotrophic 
factors such as GDNF and BDNF. In-vitro studies have shown both cell types have a higher potential to 
differentiate towards Schwann-like cells when exposed to chemical inductions geared towards neural 
differentiation. In-vivo performance of these cells in peripheral nerve injuries have shown promising results 
with the majority of studies reporting a significant improvement in nerve repair as opposed to neural grafts 




if this should be translated to clinical assessment ADSC appears to be the more preferred choice for nerve 
repair. 
1.4.2 Neural-Fate Pathways 
Human MSC (hMSC) have shown the potential for induction into cells that exhibit characteristics often 
found in cells of the ectodermal lineages [52]. Investigations have found that, under the right chemical 
induction parameters, In-vitro hMSCs can express surface markers, ectodermal protein and gene 
modulation, and re-orient their cytoskeletal structures to resemble that of neuron, astrocyte, or glial cells. 
Neural differentiation of hMSCs can be further modulated through mechanical niches stimulated by both 
physical and topographical cues presented on the surface of surrounding tissues and biomaterials. While 
these cells will resemble certain traits of neuronal cells, to date there is no protocol developed that can 
differentiate mesoderm cell lines into functional neuronal cells, which is a major limitation for using 
mesoderm cells for repair of peripheral nerves.  
1.4.2.1 Biochemical Induction  
The ability of multipotent cell lines to differentiate towards multiple cell types is in part regulated by the 
activation of specific intracellular pathways at different intensities and at varying stages during their 
development into specialized cells. Specific intracellular pathways are essential in regulating the neural fate 
of multipotent cells. Activation of these pathways can guide multipotent cells, not designed to differentiate 
towards neural lineages (MSCs, NCSCs) towards neural-like cell lineages [53].  
Cyclic-adenosine-monophosphate (cAMP) a common intracellular messenger protein responsible for 
regulating the activation of protein kinase A (PKA), cAMP has been found to be an essential component in 
regulating the modulation of genes present in neural development such as c-fos, brain derived neurotrophic 
factor (BDNF), or tyrosine hydroxylase (TH) in MSC cell lines. Use of PKA inhibitors to induce neural-
like differentiation in hMSC have been shown to be ineffective in successful neural differentiation, while 
the use of compounds that will upregulate PKA pathways would result in neural-like differentiation of 
hMSCs. This would indicate that regulation of PKA pathways are a considerable factor involved with 
directing MSCs towards neural lineages. Induction of the PKA pathway has been mitigated by either 
increasing cAMP production using forskolin, or 8-bromo-cAMP, or by preventing cAMP break down by 
inhibiting phosphodiesterases using dibutyryl-cAMP (db-cAMP), or 3-isobutyl-1-methylxanthine (IBMX). 
This method has shown evidence of early morphology changes observed in neurons such as cytoskeleton 
reorientation, and cells expressing proteins for neural markers associated with neuronal development such 
as βIII-tubulin (Tuj-1), neuron-specific enolase (NSE), microtubule-associated protein-2 (MAP-2) and glial 




development such as growth factor protein- 43 (GAP-43), and minimal presence of neurotransmitters or 
voltage-dependent Na+, P+, or Ca+2 cations leads many to conclude that neurite formation is not authentic 
and is a result of culture conditions rather than activation of a differentiation process.  
Retinoic acid (RA) is a metabolite created through retinol dehydrogenase (RoDH) of retinol. RA will bind 
specifically bind to cellular RA binding protein (CRABP) which will regulate primarily Hox gene 
activation, which is thought to be an important gene sequence for modulating anterior/posterior neural 
mapping during fetal development. A study compared the neural stimulation of MSC by activating cAMP 
pathways to that of activating RA pathways. The results found that both cAMP and RA stimulation would 
differentiate MSCs to positively express neurogenic surface markers NSE, Tuj-1, and GFAP. It is also 
shown that using these two stimulants together can result in higher expression of these markers, including 
expression of normal resting potentials and increases in calcium concentrations to that of native neural cells. 
This form of stimulation has also shown potential to express electrophysiological changes in multipotent 
cells has shown in a study involving neural stimulation of dental pulp stem cells (DPSC) that expressed 
active sodium voltage-gated ion channels, which could be an essential component for differentiating 
mesoderm cells towards functional neurons.      
  
Neurotrophic growth factors (NGF) are essential in maintaining normal neural cell functionality and 
survival, while under certain forms of stress can be upregulated to guide neural cell fate in neural stem cells. 
This family of proteins involve NGF, BDNF, GDNF, and neurotrophins (NT- 3, 4, 5, and 6). NGF and 
neurotrophins have a high affinity towards tyrosine kinase receptors A, B, C (TrkA, TrkB and TrkC), GDNF 
affinity towards GDNF family receptor alpha-1(GFRα) and RET proto-oncogene (RET), and NGF and 
BDNF affinity towards P75 receptors. Signal transduction will then follow one of three pathways: mitogen-
activated protein kinases (MAPKs), phospholipase C (PLC), or phosphatidyl-inositol-3-kinase (PI3K). 
These pathways will further phosphorylate towards PKC, protein kinase B (PKB), or ERK which will 
transcript gene sequences that will regulate neuronal development, health, and synaptic functions. By 
themselves, neurotrophic factors will initiate neural differentiation in neural stem cells while initiating 
neural-like cell differentiation in Mesodermal cell lines to varying degrees. Combined with other neural 
pathways will further enhance expression of neural traits in mesodermal cell-lines. 
  
Wnt pathway involves proteins that are involved in regulating homeostasis in adult tissue and early stages 
of tissue development during embryogenesis. This includes early neural development from neuronal stem 
cells by regulating stem cell fate, proliferation, and survival as neuronal cells. Wnt proteins will first activate 




the cytoplasm which will then regulate T-cell specific transcription factors (TCF) gene sequences specific 
to the type of stem cell. This pathway is geared to differentiate stem cells based on their respective 
phenotype, where mesoderm stem cells will most likely be guided toward smooth muscle and endothelial 
cell fates neural stem cells will be guided towards neuron cell fates. By its self, the Wnt pathway cannot 
successfully initiate differentiation of MSC towards neuronal fates. However, when combined with other 
stimulation pathways previously discussed will express other neuron markers such as Ngn1, NeuroD, and 




Figure 1.5 Current identified pathways for induction of MSC towards neural-like cells 
Source:  Neirinckx, Virginie, Cecile Coste, Bernard Rogister, and Sabine Wislet-. 2013. “Neural Fate of Mesenchymal Stem Cells and Neural Crest 
Stem Cells: Which Ways to Get Neurons for Cell Therapy Purpose?” In Trends in Cell Signaling Pathways in Neuronal Fate Decision, edited by 










The topics discussed in this chapter provide the frame work for understanding peripheral neuropathies and 
the methods for repairing critical size nerve defects and their limitations. It is also discussed the approaches 
of using both biomaterial and stem cell therapies together as a potential novel alternative method for repair 
of critical size nerve defects. Biomaterial conduits or wraps arranged as an open tube structure are the most 
commonly studied alternative repair option for severe neurotmesis. It is clear that the addition of stem cell 
therapies can improve the quality of neural tissue growth along the scaffold channel by introducing 
immunomodulatory effects and promoting axonal growth and minimizing muscle atrophy by expressing 
neurotrophic growth factors at the site of injury. While GFNs are currently under investigation for their 
toxicity in physiological models, In-vitro and In-vivo studies have shown that GO films not only serve as a 
suitable platform for delivering MSC therapies but also has neurogenic potential as a possible surface 
coating additive to neural conduit and wrap designs for nerve healing applications. 
From this chapter it is clear that many approaches to designing different neural wraps using synthetic 
polymers and GO coating modifications are possible, with many iterations still unexplored. It is the goal of 
this study to design a 3D neural wrap composed of PCL synthetic biomaterial and surface coat with GO as 
a platform suitable to grow hADSC cultures. The function of this design is focused towards bridging critical 
size nerve defects to assist in axon guidance and stimulate nerve healing. It is also designed as a deliver 
platform to transport hADSC cultures to the injury site for further assist by providing immunomodulation 
and release of neurotrophic factors. By manufacturing this material and testing its cytocompatability 
towards supporting hADSC cultures In-vitro and tests its ability to assist in neural healing In-vivo, this 
should provide data that will determine this designs potential in providing assistance in nerve healing 
applications.   
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Chapter 2: PCL Electrospin Film with GO Surface Modification as 





Critical size neural defects have a devastating impact on people’s wellbeing and has a substantial 
component in the overall health care cost of both acute and chronic pain patients. The current gold standard 
for repair of critical nerve defects has limitations that require alternative solutions to address these. This 
has expressed much interest in the development of new biomaterials that can provide support and protect 
new axonal growth as a component of a stable film or mesh known as a neural wrap device. It is suggested 
that a new neural wrap design composed of electrospun PCL with the addition of surface coating of GO 
and potential to support hADSC cultures to deliver stem cell therapies could have the potential for assisting 
the repair of critical nerve defects In-vivo. In this study, the ability to manufacture this type of material and 
its biocompatibility towards MSC lines and ability to support hADSC cultures under neural stimulation is 
determined. Thru our collaboration with the University of Arkansas Little Rock, we were able to 
manufacture graphene coatings of different oxygen content for biocompatibility assessment and create 
different PCL films to assess how hADSC cultures behave on its surface under normal and neural induction 
conditions. The results of the proliferation and viability assay of rat ADSC cultures on graphene coatings 
showed GO coating had the largest proliferation and viability levels compared to all other graphene 
iterations tested. We applied GO coating to the smooth surface and fibrous surface PCL platforms and 
assessed the prescence and neural expression of S100β on hADSCs at day 1 incubation and the presences 
and morphology of hADSC cultures at day 6 incubation using vimentin staining. Results showed that PCL 
fiber mesh surfaces modified with GO could support hADSC cultures under normal and neural induction 
In-vitro environments. Slightly more impressive cell morphology and organization was detected on PCL 
platforms of nanofiber topographies, suggesting that PCL fiber meshes with GO surface modifications is 
the preferred material composition to use moving forward to test the materials potential in a critical nerve 










2.1 Neural Wrap Manufacturing  
2.1.1 Introduction 
Peripheral neuropathy (PN) is a condition of the peripheral nerve system that currently affects over 20 
million US citizens, with a prevalence of 3% in all trauma patients showing some form of peripheral 
neuropathy. Neurotmesis is the most severe type of peripheral injury where the nerve segment is completely 
transected cutting of the action potential to all sensory and motor functions. Often classified as a grade 4 or 
5 on the Sunderland nerve injury classification scheme [1–3]. Patients with neurotmesis will often 
experience symptoms of both acute and chronic motor weakness and abnormal sensory function that overall 
diminish the quality of life for patients [4]. Almost all neurotmesis injuries require surgical intervention to 
ensure the nerve heals properly to regain most of its functionality. Severe neurotmesis involves significant 
gaps (>2-3 cm) that require surgical placement of neural grafts to insure proper guidance of axons as they 
grow across the gap [5]. Currently, the gold standard for repair of severe neurotmesis is the use of autograft 
nerve segments taken from the patient [6,7]. However, this method is limited in the degree of healing 
possible at the damage site [8]. Surgical protocols require precise matching and orientation of the graft at 
the two ends of the gap which is very difficult given the nature of microsurgery. The suturing of the graft 
can rupture or pierce the perineurium around the fascicles, causing scar tissue to form which can cause 
further problems at the site as iatrogenic peripheral neuropathy. The outcome of this strategy usually 
involves the following implications: donor-site morbidity, sensory loss, scarring at the donor site, neuroma 
formation, pain, and in the case of allografts long periods of host immunosuppression [9,10]. The low 
quality of recovery for neurotmesis cases results in a surplus of patients affected by chronic peripheral 
neuropathy symptoms, contributing to an overall decrease in the wellbeing of the population and an increase 
in the health care costs utilized for repair and management of these symptoms which are currently estimated 
at around $150 billion annually. This presents a pressing need to research new alternative strategies to 
autografts for nerve repair that addresses these limitations while minimizing the onset of new ones.  
Tissue regeneration is currently a topic extensively studied within the field of both human and animal 
medicine that has potential for improving the rate and quality of healing damaged tissue. One important 
field of study in this topic is the use of scaffolds composed of biomaterials designed to support and promote 
activation of cell lines committed towards assisting in the healing of damaged tissue. Studies have shown 
that mesenchymal stem cells (MSC) can improve the healing of damaged tissue by differentiating into 
multiple cell lineages that can promote the healing of damaged tissues. Studies have also shown that 
graphene oxide (GO) as a thin film material has low cytotoxicity, excellent cell absorption properties, and 
can support cultures of adipose derived stem cells (ADSC) over extended periods of time. For the 




a scaffold design that can support neural differentiated ADSC cultures while enhancing nerve regeneration 
at the site of healing. One important aspect of this design is selecting an appropriate biomaterial as a 
platform that can support GO films and ADSC viability over an extended period of time. Biocompatible 
synthetic polymers such as polycaprolactone (PCL) have been shown to be acceptable materials for 
supporting both thin films and ADSC for extended periods of time In-vivo. To our knowledge, the design 
of a PCL wrap has not yet been explored as a suitable platform to support GO thin film in combination with 
hADSC cultures to assist in peripheral nerve repair. 
2.1.2 3D Fabrication of Neural Wrap  
Previous studies have looked at the inclusion of PCL as a synthetic platform for assisting peripheral nerve 
healing with studies finding that PCL remains mechanically stable during the period of repair in small 
animal models and as a polymer with high solubility to organic compounds it can be utilized in a variety of 
manufacturing techniques to tailor fit a design that meets the design criteria of a successful neural wrap. It 
also is classified by the FDA as a biodegradable polymer of up to 2 years before hydrolytic degradation 
renders the design mute with the only residuals having little to no toxic effects to the physiological 
surroundings. Previous studies have also found that biomaterials with certain micro or nano- surface 
topographical feature are better suited to assisting in peripheral nerve stability and guidance during repair. 
Surfaces of high surface area that conform to groves or channels have been found to enhance neural cell 
migration and differentiation under the right conditions compared to smooth surface platforms. A novel 
method that has been used extensively in polymer-based manufacturing to produce surfaces saturated in 
micro channels and groves electrospinning of polymers into nanoscale fibers that act as channels or tracks 
that are preferred adhesion points for newly regenerating nerves.  
 
 
Figure 2.1 Common horizontal electrospinning apparatus setup 
Source:  Kadavil, Hana, Moustafa Zagho, Ahmed Elzatahry, and Talal Altahtamouni. 2019. “Sputtering of Electrospun Polymer-Based 




Electrospinning is a technique that involves drawing charged polymers in solution towards a grounded 
collecting plate using electro repulsion forces. If polymers are successfully suspended in a compatible 
soluble solution and the solution is capable of holding a charge then it has the potential for electrospinning 
manufacturing. If the solution is charged by a generator and a grounded collector is located a distance from 
the solution reservoir, electro repulsive forces created from the opposite charges will attract and pull the 
solution and its monomer components towards the collector. The process of pulling the charged polymer 
solution from its reservoir towards the collecting plate until the forces exceed the surface tension forces of 
the solution to create the jetting effect is called the Taylor cone, and is an effect that should be present for 
successful solution spinning. As the solution and monomers are pulled across the air medium, the monomers 
align together as the solution evaporates and cross links them into a continuous fiber strand [11]. By 
changing the polymer percentage solution, voltage, tip-to -collector distance, and solution pump rate the 
diameter of the fibers can be tailored to specific fiber diameter, surface topography, and porosity 
specifications.  
The development of neural scaffolds using synthetic electrospun polymers that provide both cellular and 
mechanical support at the site of healing and can be designed to biodegrade after its therapy has finished 
without inducing any adverse immune or cytotoxic effects [12]. This technique has gained much interest 
for addressing the limitations of autografts while providing the advantages of tailoring biocompatibility, 
biodegradation, mechanical properties, and surface architectures of the scaffold based on the materials used. 
This provides opportunities to test a variety of different materials in the hopes of creating the ideal scaffold 
design [13]. Currently, synthetic polymer scaffolds by themselves still underperform when compared to the 
current gold standard for defects greater than 1 cm. To address this challenge, many studies have begun to 
look at combining multiple TE techniques together in the scaffold design such as stem cell support, 
anisotropy surface architecture, and surface coatings to improve the limitations of synthetic scaffolds [14]. 
The majority of these In-vivo studies show a significant improvement in neural repair, with successful 
bridging of neural defects up to 3 cm in length being reported. We are particularly interested in developing 
synthetic neural scaffold designs that incorporate stem cell therapy and surface coatings to improve the 
quality of severe neurotmesis recovery.  
2.1.3 Graphene Family Nanomaterial Inclusion  
We are interested in studying the application of using graphene-based materials as a thin film coating 
applied to the surface of scaffolds to potentially enhance growth, survival, and rate of differentiation of 
hADSC for promoting tissue healing [15]. Graphene is a single atom thick honey comb lattice structure of 
carbon bonds that consist of SP2 and SP3 hybridizations. Graphene has been studied for its potential as a 




found to be one of the most promising candidates as a biocompatible substrate. Both graphene oxide thin 
films and hADSC have been studied extensively for their potential to enhance the repair of damaged 
peripheral nerve [16–18]. Results show a marked improvement of neural repair in the presence of hADSC, 
graphene-based materials, or both. Current studies have also shown that by treating the surface of 
biomaterials with carbon based thin film coatings, we can enhance the growth, survival, and differentiation 
of mesenchymal stem cells, supporting the notion that combining graphene-based thin films with ADSC 
cultures to our neural scaffold might enhance nerve repair [19,20]. 
2.1.4 Objective 
The objective of this project is to determine whether electrospun PCL platform surfaces coated with 
graphene nanomaterial is a suitable platform to support MSC cultures differentiated towards a neural 
phenotype. This objective is the first iteration of In-vitro tests that will assess the cytotoxicity, and potential 
to support hADSC artificially stimulated towards Schwann-like cell phenotypes as the first initial set of 
data for support in progressing our novel therapeutic design towards In-vivo assessment studies that will 
result in the design of a 3D neural wrap functioned to support and guide peripheral nerve healing. We 
hypothesize that PCL films coated with GO nanomaterial films will successfully attach to the PCL film 
iterations and that they will show a high potential for supporting hADSC and neural differentiated hADSC 
cultures compared to controlled PCL films without GO coatings.  
2.2 Experimental Neural Wraps 
2.2.1 Graphene Solution Preparation  
With a joint collaboration between the University of Tennessee’s CVM department and the University of 
Arkansas Little Rock (UALR) Nanotechnology center, we created graphene and PEG coated coverslips 
using techniques originated from the work of UALR as described in (Majeed, Waqar, 2017). 8 iterations of 
graphene solutions and PEG solution were created based on the surface coat non-tissue glass cover slips to 
determine the optimal surface coating to use on PCL meshes for supporting MSC cell lines. N002-PDR PG 
(Angstron Materials) with x-y dimensions of 10µm and ≤2.5% oxidative group content, single-layered GO 
(Cheap Tubes) with x-y dimensions 300-800 nm and 35-45% oxidative group content, and PEG of 8,000 
molecular weight (Bioworld) where acquired. 0.1mg/ml PG solution was created by adding 3.0mg N002-
PDR PG with 18MΩ deionized water.  High-Oxygen Graphene (HOG) solutions used N002-PDR PG for 
their preparations. Both solutions were oxidized using similar volume ratios of concentrated sulfuric acid 
(H2SO4) to concentrated nitric acid (HNO3)- 3H2SO4: 1HNO3:  For the HOG solution, the acid volume ratio 




solution to 3H2SO4: 1HNO3: 1H2O ratio prior to filtration. 0.1mg/ml single-layered GO solution was created 
by adding 3.0mg single-layered GO with 18MΩ deionized water. All graphene solutions were vacuum 
filtered and washed with 18MΩ deionized water several times to collect graphene precipitants. All graphene 
iterations solutions with the inclusion of PEG (HOG+PEG, GO+PEG) follow the same protocol as 
discussed previously with the inclusion of 8,000 molecular weight PEG at 0.1mg/ml. all solutions had 30 
ml of 18MΩ deionized water added. All solutions where tip sonicated for 2 hours after filtration step. 
2.2.2 Air Spray Surface Coating (24-Well Plate)   
Thin film surface coating of graphene solutions onto glass cover slips and PCL meshes was achieved using 
a Paasche series airbrush kit. Under chemical fume hood conditions, two 24-well plates aligned next to each 
other was placed on a hot plate set to 50-55˚ C. Glass cover slips were taped to the bottom of each well to 
prevent cover slips from being up lifted from the wells during spraying. The last 12 wells on each end of 
the plates were taped off to prevent cross contamination during coating phase (Figure 2.2). All solutions 
were bath sonicated 30 min to evenly disperse graphene oxide films in solution that have settled to the 
bottom of the container after 24 hours or more in storage before being used to coat the materials. 10ml were 
used from each graphene and PEG solution to coat 24 wells per plate. Solutions were sprayed at 21 psi. A 
total of 10 plates for graphene and PEG iterations including positive control plates with cover slips and a 
total of 2 plates for graphene and PEG iterations including positive and negative control plates with smooth 
and fiber PCL films. Plates were covered with parafilm after coating and UV sterilized for 4 hours under 
cell culture sterile hood prior to culturing cells. 
 
          
Figure 2.2 Air spray setup for graphene coatings on 24-well plates   
Note: 24-well plates on hot plate chemical fume hood conditions for manufacturing graphene/ PEG surface coated glass cover-slips, and PCL 





2.2.3 Electrospinning  
Poly-caprolactone of 80,000 molecular weight (Sigma Aldrich) was used to create PCL solutions for both 
electrospinning and drop coating manufacturing techniques. Electrospinning solution of 10% wt. PCL was 
created using 1.5mg PCL powder to 15ml 1:1 ratio of Methylene Chloride (MC) to Dimethylformamide 
(DMF). Electrospinning apparatus was setup under chemical fume hood conditions with an Aladdin-6000 
multi-barrel programmable 6 syringe pump (World Precision Instrument), a 5ml syringe, 19 gage needle 
head, voltage generator attached to the needle head, and a rotating mandrel collector wrapped with 
aluminum foil grounded to the fume hood box. Electrospinning parameters were set to 16-17.5 kV charge 
with the needle tip-to-collector distance set to 7 in and the solution pumping rate set to 1 ml/hr. 15mm non-
tissue culture treated glass cover slips were attached to the collector. Each electrospin process used 4 ml of 
the 10% wt. PCL solution to create thick PCL meshes of random fiber orientation. PCL meshes were 
deposited on the surface of cover slips making it easy to separate into individual circular sections that fit 
into non–tissue culture treated 24-well culture plates for cytotoxicity assessment. PCL meshes along with 
24 well plates were placed under UV sterilization for 4 hours prior to culturing cells.         
2.2.4 Drop Coating  
Drop coating solution of 5% wt. PCL was created using 0.75mg PCL powder to 15ml Chloroform. Under 
chemical fume hood conditions, glass cover slips were placed on top of leveled glass plates. A 200 µl pipette 
was used to load PCL solutions onto cover slips. A beaker was placed on top of the cover slips while 
chloroform evaporated. Smooth PCL films remained once all chloroform evaporated and placed into 24-
well culture plates. PCL smooth films were placed under UV sterilization for 4 hours prior to culturing 
cells.  
2.2.5 Rat/ Human ADSC Culture 
Passage 3 rADSCs and hADSCs cell lines were acquired from The University of Tennessee Medical Center 
Laboratory for Regenerative Medicine headed by Dr. Tom Masi and Dr. Stacy Stephenson. Both cell lines 
were previously assessed for mesenchymal cell quality by observing their potential for differentiation 
towards cell lineages expected of cells that follow a mesenchymal cell pathway (tri-lineage testing), cell 
surface marker profile, and proliferation capacity under normal culture conditions. Non-tissue culture 24 
well plates with glass cover slips surface coated with graphene and PEG iterations were seeded with rADSC 
culture for MTS and Calcein AM/PI assessment of cell viability. All wells were seeded with a cell density 
of 20,000 cells/well, suspended in 500 µl of DMEM-F12 cell culture media (DMEM-F12 +10% fetal bovine 
serum+1% L-glutamine+ 1% penicillin streptomycin). Wells were kept in incubator set to 5% CO2 and 37˚C 




Non-tissue culture 24 well plates with both electrospun (fiber) and drop (smooth) coated PCL films with 
surface coated graphene and PEG iterations were seeded with hADSC cultures for cell differentiation and 
protein expression assessment. It has been observed in previous studies that during neural regeneration  that 
there is a marked increase in cAMP messenger proteins in axons as a result of membrane depolarization of 
Ca ion channels, thus regulating neurotrophic growth factors and axon extension during repair[21,22]. Our 
protocol for elevating intracellular cAMP to artificially induce hADSC towards cells with neural like 
characteristics was similar to the methods used in[23,24]. Primary induction medium consisted of 0.5 mM 
3-isobutyl-1-methylxanthine (IBMX) and 1 mM dibutyl cyclic adenosine monophosphate (db-cAMP) per 
well with the addition of 500µl of DMEM-F12 cell culture media. Wells were kept in incubator set to 5% 
CO2 and 37˚C during the culture period. Regular media changes were scheduled at day 3 and 5.   
2.2.6 MTS Assay 
Tetrazolium is a redox indicator commonly used to quantify the number of viable cells in a controlled area. 
The compound is positively charged in its initial form and when combined with negatively charged 
phenazine methosulfate it becomes a stable macromolecule in aqueous solution. It is permeable to the 
cellular and mitochondrial membrane for most cell types, giving tetrazolium easy access to metabolically 
active sites of cells. When tetrazolium is positioned in the mitochondria it is bio reduced by dehydrogenases 
enzymes. The electron from NADH or NADPH is passed to the tetrazolium molecule and yields a 
compound called formazan. The formazan compound is a chemically stable dye that will bind to the cell 
surface and is soluble in aqueous solution. By measuring the absorbance of light from the dye we can 
quantitatively determine how many viable cells are in a given culture area and over time observe if the 
number of cells increase or decrease as an indicator of cell growth or death. Each coating had a sample size 
of n=5 wells for culture time points day 3, 5, and 7 with 1 negative control blank well at each time point to 
normalize MTS values from background absorption given off by the wells material and the culture 
media   MTS cell proliferation quantitative analysis was carried out at these time points using CellTiter 96 
Aqueous one solution (Promega). At each time point, the old media was removed and replaced with fresh 
media. MTS reagent was added to each well at a 1/5 dilution ratio. Well plates were left in 5% CO2 and 
37˚C incubator for 3 hours to allow ample time for MTS reagent to react with cells. Using an Epoch Biotek 
micro-plate reader set to detect 490nm UV-Vis absorption, we quantified the formazan intensity of each 
coating and compared them to positive control tissue culture treated glass cover slips. 
2.2.7 Calcein AM, Propidium Iodine Live Stain 
Calcein AM is a fluorescent dye that is permeable to live cell membranes. Intracellular esterase removes 




excitation and 520 nm emission. Commonly utilized as a visual indicator of live cells and for temporary 
tracking of live cells in culture. Propodeum Iodine is a red fluorescent dye that is impermeable to live cells, 
which makes it useful in labeling and tracking dying cells present in a culture area. The dye will bind with 
DNA by intercalating between base pairs, where the dye is expressed at 488 nm excitation and 617 nm 
emission. Both reagents were acquired as Cell Trace Calcein green AM 5µg/µl (ThermoFisher), and 
Propidium Iodine 1.0mg/ml (ThermoFisher). A combined solution of calcein AM (5µg/ml HBSS) and PI 
(0.5 µg/ml HBSS) was created. Old media from the well at each time point was removed and washed twice 
with HBSS to remove any floating dead cells or debris that could obstruct visualization of the dyes. 0.5 ml 
of calcein/ PI solution were dispensed into wells and left in 5% CO2 and 35˚C incubator for 30 min to allow 
ample time for reagents to react with cells. Using a Light Fluorescence Microscope, we visualized surface 
area coverage of calcein AM and PI fluorescence on coverslips.  
 2.2.8 Immunofluorescence 
Vimentin is an intermediate filament protein highly concentrated in the cytoplasm of mesenchymal based 
cell lines as a primary component of the cytoskeletal structure for cell mobility and spreading and therefore 
can act as a quality control marker during immunofluorescence protocols [25]. DiI is a lipophilic stain that 
labels the bilayer of the cellular membrane of live cells. It is often used as a cell tracking stain that will 
label the cells for long periods of time without impacting normal cellular physiology. This will allow for 
tracking of hADSC cultures seeded on biomaterials during the entire differentiation period. S100 protein 
are responsible for regulating Ca+2 levels, which are involved with different cellular pathways that regulate 
cell growth, cytoskeletal activities, and inflammatory responses. S100β protein is a subsidiary of the S100 
family and is specific to glial cells, particularly astrocyte cells that function to regulate axon proliferation 
and neurite extension by controlling Ca+2 intracellular levels [26,27]. Vimentin present in hADSC cultures 
is expected to show changes in morphology similar to that of neural based cells by day 6 when stimulated 
with this  specific neural induction media. Changes in S100β expression is expected in hADSC by 24 hours 
post neural induction with this specific neural induction media as an indicator of neural differentiation.  
Immunolabeling was performed on MSCs plated on coated glass coverslips. 24 well-plates were divided 
into 2 equal sections with wells that received normal DMEM F-12 media and wells that received neural 
stimulant media. DiI staining of all immunofluorescence wells was performed on the same day of cell 
seeding to track cell growth over the culture period. Cells were fixed at 24 hours post-cell seeding at 6 days 
post-cell seeding. Cells were fixed in 4% Paraformaldehyde for 10 minutes. Washed wells with HBSS 
containing 0.1% Triton X-100 and let sit at RT for 10 min. wash twice with HBSS and blocked with 1:10 
protein block for 30 min at RT. Wells fixed at day 1 were then incubated with 1µg (4µl) Unconjugated 




were incubated with 1µg (2µl) Unconjugated Purified mouse anti-vimentin, 0.5µg/ml (BD Pharmingen) at 
1μg/well. Primary antibodies were added to 1:10 protein block solution at 500 μl/well and left overnight at 
4°C. Primary antibody solutions were removed from wells and washed twice with HBSS. Secondary 
antibody AlexaFluor 488 Donkey, anti-mouse IgG, 2mg/ml, (Invitrogen) at 4μg/well (2μl) to 1:10 protein 
block solution at 500 μl/well and incubated for 30 min at RT. Wash wells with HBSS before mounting 
samples onto glass slides using 1 drop of DAPI Prolong Gold antifade reagent (Molecular Probes). 
2.3 Results 
2.3.1 MTS Analysis  
MTS results of HOG and HOG+PEG coating showed significant increase in formazan fluorescence from 
day 3 to day 5, with fluorescence intensity leveling off at day 7 for HOG coating and a continued linear 
proliferation projection for HOG+PEG towards day 7. GO, GO+PEG, and PEG coatings showed continued 
significant increase in formazan fluorescence at each culture time period reaching a peak proliferation 
intensity at day 7 statistically similar to that of the positive control coverslips. HOG and HOG+PEG 
coatings appear to have moderate viability potential with proliferation reading showing significantly less 
formazan intensity at day 7 compared to positive control coverslips. GO, and GO+PEG was the only 
graphene-based coatings that showed significantly similar levels of rADSC viability at day 7 compared to 
the control coverslips (Figure 2.3).   
   
 
Figure 2.3 Rat ADSC MTS Analysis on Graphene Iterations  





























Day 3 Day 5 Day 7
HOG: High Oxygen Graphene
HOG+PEG:High Oxygen Graphene with Poly-ethylene glycol
GO: Graphene Oxide
GO+PEG:Graphene Oxide with Poly-ethylene glycol
PEG: Poly-ethylene glycol






2.3.2 Live/Dead Calcein AM Propidium Iodine Stain 
Calcein AM and PI Live/dead stains were analyzed under fluorescent microscope with images taken at the 
center of each 24-well. Minimal PI dye was detected on each coating iteration most likely due to the process 
of washing each surface coating twice with HBSS solution before applying staining solution, thus removing 
any loosely adhered or floating dead rat MSCs to stain with PI. The images of positive Calcein AM staining 
for all coatings at day 7 are shown in (Figure 2.4). The qualitative assessment of these images indicates 
that live rADSC cultures are present on each iteration of graphene coating at day 7. Quantitative assessment 
of the intensity of calcein stains was performed using ImageJ by grey scaling the green fluorescence of 
calcein and measuring the total area coverage of the stain at five random locations at day 7 5X images with 
no replicates (Figure 2.5). Quantitative assessment showed that positive control material had significantly 
higher positive calcein coverage at day 7, compared to all other coating iterations. 
   
 







Figure 2.4 Calcein AM staining of hADSC cultures on graphene iterations  
Note: Day 7 single 24-well sample of each Graphene/PEG surface coating iteration thru air spray techniques. 5x magnification using fluorescent 
microscope directed at center position of each 24-well. Calcein AM stained green as an indicator for viable cells present on surface coating iterations. 
Rat ADSC (Control) Rat ADSC (GO) 
Rat ADSC (GO+PEG) 
Rat ADSC (PEG) 





Figure 2.5 Day 7 Calcein AM average area coverage quantification 
Note: Day 7 Calcein Am staining for GO and HOG coating iteration and PEG surface coating as an indicator of cell viability. Surface area coverage 
measurements were taken at n=5 random locations selected on each 5X magnification using ImageJ. ANOVA analysis of day 7 calcein coverage 
relative to the control well. *P ≤ 0.05    
 
2.3.3 Day 6 Immunofluorescence-Vimentin   
Vimentin proteins were visualized on day 6 of hADSC culture period using a fluorescent microscope. 
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Vimentin along with its counter DiI and DAPI showed positive on positive control glass cover slips under 
both neural and control induction media. smooth PCL under control media did not show positive expression 
of vimentin counter stained with positive DiI and DAPI at day 6 culture, while this material under neural 
induction media did show positive expression of vimentin counter stained with DiI and DAPI at day 6. Both 
the smooth PCL+GO and smooth PCL+GO+PEG iterations under neural and control media at day 6 showed 
positive expression of vimentin counter stained with DiI.Control media showed cellular spreading 
morphology, while neural induction showed profound extensions of the cell from the nucleus similar to 
bipolar cell morphologies. All fiber mesh iterations showed either negative expression of vimentin or 
vimentin expressions difficult to make out cell morphologies even when countered stained with DiI and 
DAPI. Vimentin and DiI staining showed that clear stable cell morphologies were profound on PCL 
platforms with smooth surface topography by day 6 culture period, while PCL fiber mesh platforms showed 
little indication of morphology or cell culture presence on the mesh surface. 
2.3.4 Day 1 Immunofluorescence-S100β  
S100β protein expression was visualized on day 1 of hADSC culture period using a fluorescent microscope. 
Images were taken at 20X magnification. S100β along with its counter DiI and DAPI showed positive on 
positive control glass cover slips under both neural and control induction media at day 1 culture. PCL 
material of both smooth and fiber topography induced by neural or control media showed low or negative 
expression of S100β at day 1, while smooth PCL showed positive counter stain of DiI and DAPI and fiber 
PCL showed positive DAPI expression at day 1. Both smooth PCL+GO and smooth PCL+GO+PEG 
iterations under neural and control media showed positive expression of S100β counter stained with DiI at 
day 1. Control media showed cellular spreading morphology, while neural induction showed profound 
extensions of the cell from the nucleus similar to bipolar cell morphologies. fiber PCL+GO meshes showed 
positive expression S100β counter stained with DiI under neural and control media at day 1. Profound 
elongation of hADSC along with parallel orientation and organization of cells relative to each other is 
present on Fiber PCL under neural and control media at day 1. Results show positive expression of S100β 
on PCL+GO, PCL+GO+PEG smooth films and PCL+GO fiber mesh platforms with clear different cellular 
morphologies detected from DiI staining at day 1 culture period. Induction of hADSC cultures towards 
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2.3.5 Day 1 S100β Intensity  
Quantitative assessment of S100β intensity of hADSC cultured on both smooth PCL+GO films and fiber 
PCL+GO meshes at day 1 post- neural induction media was performed using ImageJ by grey scaling the 
green fluorescence of S100β and measuring the maximum intensity of the stain across the length of 10 
randomly selected hADSC cell bodies in 5X images (Figure 2.8). Analysis showed that the intensity of 
S100β expression on control glass exposed to control media induction was significantly similar only to 
the PCL+GO fiber meshes exposed to control media. All other iterations had S100β intensities 
significantly greater than the control glass under control media. Under neural induction media, Fiber 
PCL+GO meshes showed similar S100β intensities to that of the control under neural induction media, 
while all media iterations on smooth PCL+GO films had the highest S100β intensities compared to all 
other groups. Results indicate that fiber PCL+GO mesh S100β intensities under neural induction at day 1 











    












Figure 2.9 S100β intensity profile for hADSC  
Note: hADSCs cultured under normal and neural induction media on PCL fiber and smooth platforms surface coated with GO. ANOVA analysis 
*P ≤ 0.05 
 
2.4 Discussion 
Electrospinning and drop coating techniques resulted in thin film surfaces of PCL biomaterial composition 
with either nanofiber or smooth surface topographies to be tested as platforms for delivering hADSC 
therapy In-vivo.   
In the MTS Profile, coating with graphene of higher oxygen content was shown to have similar formazan 
intensity towards MSC cell model rADSC cultures compared to the control material (GO, GO+PEG, and 
PEG only) while HOG, and HOG+PEG had significantly smaller formazan intensity compared to the 
control at day 7. Since this study is interested in utilizing graphene based materials as a coating additive 
and the GO-based coatings showed similar cytocompatibility to rADSC to that of the control it was decided 
to continue further In-vitro studies using GO-based coatings on PCL platforms, even though PEG-only 
coating showed the same degree of cytocompatibility to that of the GO-based materials. Positive expression 
of calcein stain on graphene surfaces showed rADSC cultures at day 7. The coverage of calcein AM staining 
at day 7 images for each graphene coating shows a similar quantitative projection to that of the formazan 
intensity detected thru MTS suggesting that there might be a correlation of formazan fluorescence intensity 



















































Observable differences in cell morphology and S100β expression intensity was detected between coatings 
of different media and surface topography groups. Immunofluorescence expression of DiI, S100β, and 
DAPI for positive control glass coverslips under neural and control media induction at day 1 culture period 
was positive, indicating correct immunofluorescence protocol. Control material showed low intensity of 
S100β under control media compared to neural media group, indicating a low expression of S100β in 
undifferentiated normal hADSC cultures compared to neural induced hADSC cultures. Fiber mesh and 
smooth film samples for PCL+GO showed positive expression of S100β and DiI staining. Fiber PCL+GO 
mesh showed similar S100β intensity profile to that of the control material under different media groups. 
Smooth PCL+GO showed a higher intensity of S100β under control media group compared to the neural 
media group. This difference in S100β intensity between the media groups could be attributed to 
background expression of S100β, or might be attributed to the difference in surface topographies between 
the PCL film and mesh groups. While the control material and smooth PCL materials showed general 
spreading under control media and profound extensions under neural media, the fiber PCL materials under 
both media groups showed additional parallel orientation and organization that we would expect to b present 
during endogenous nerve repair. While most iterations of human mesenchymal stem cells show very little 
to no expression of S100β in undifferentiated form, in the presence of GO coating, specific surface 
topographies and, neural stimulants could account for the differences seen in S100β and the cellular 
morphologies in those groups. This indicates that PCL materials with fiber surface textures and coated with 
GO has potential to not only support neural differentiated hADSC but stimulate specific growth patterns of 
hADSC during differentiation. 
Immunofluorescence expression of DiI, vimentin, and DAPI for positive control glass coverslips at day 6 
culture period was positive, indicating correct immunofluorescence protocol and antibody concentrations 
in 24-well plates. Our experimental nerve wrap material PCL+GO, and PCL+GO+PEG expressed positive 
for vimentin along with counter stain DiI. DAPI was found to be difficult to image on materials coated with 
GO but the presence of cell spreading and extensions by cells expressed by vimentin and DiI confirmed the 
presence of these cells on the material surface. Slight difference in cell morphology can be detected between 
the media cultures, with neural induction cells showing longer extensions from the nucleus with some 
showing a bipolar shape reminiscent of a neuron, while control media shows cell with overall large 
spreading on the platform but no profound extensions as noted in the neural media. Cell morphologies 
showed profound spreading on PCL smooth film iterations while fiber surface iterations showed cell 
morphologies with profound extensions and bipolar stretching exceeding past their original size as well as 
signs of mobility and communication with surrounding cells to orient their cell bodies parallel to each other. 
These characteristics were further enhanced by either induction by control media or neural media were 




Although vimentin expression of hADSC cultures were not profound in fiber PLC+GO meshes compared 
to smooth PCL+GO or PCL+GO+PEG by day 6 culture period, S100β expression along with DiI staining 
on fiber PCL+GO meshes was the only sample that showed positive S100β with profound cellular 
extensions oriented parallel to each other at day 1 culture period. This more closely compliments the neural 
development and organization that we want our design to incorporate In-vivo. Also, these results share some 
aspects of hADSC morphological changes at certain time points during neural induction recorded from 
studies that have referenced using this particular neural induction media recipe to assess cell morphology 
and neural potential by staining for S100β/ vimentin protein expression in hADSC [28]. 
Based on both direct and in-direct proliferation assays on MSC lines on different graphene iterations and 
the performance of these coatings to support hADSC cell lines stimulated towards neural-like 
differentiation In-vitro, GO nanomaterial films might have potential as a surface modifier of PCL fiber 
meshes for delivering stem cell and biomaterial therapies to assist in the repair of critical neural defects. It 
is also suggested from these results that the next step is to develop a functional 3D prototype of this 
biomaterial mesh design that can be implemented in a small-animal to determine initial compatibility of 
this design in critical nerve defect repair sites. 
2.4.1 Implications/ Challenges  
Neural Wrap Coating Characterization UALR’s Nanotechnology group previously characterized these 
specific graphene solutions of varying oxygen group content used in this study. In their study, UALR was 
able to identify the oxygen content and the presence of graphene on coverslips using X-ray Photoelectron 
spectroscopy (XPS) and Raman Spectroscopy techniques that identified the molecular signature of 
graphene and the oxidative group bonds as well as their percent ratios in order to identify different graphene 
iterations produced by UALR’s manufacturing methods [29]. A collaboration with the UALR 
Nanotechnology group was established to assist in replicating these graphene solutions and coating 
techniques for this study. No characterization assessment tests were performed on this studies batch of 
graphene coating iteration to determine with certainty that coating was successful or confirm the oxygen 
content of the coatings. By using UALR’s controlled lab environment, equipment, and protocols used in 
their previous study, it is assumed that the manufacturing of graphene coating iterations will have minimal 
variation in characterization variables from the graphene coatings created in UALR’s previous study. This 
study’s only means of determining successful graphene coating on material surfaces is subjective visual 
confirmation of color changes on the material surface, most commonly changes towards a dark black or 




Manufacturing While air spraying both 24-wells and PCL materials with graphene solutions by hand, it is 
difficult to maintain consistency of equal amounts of solution sprayed onto each material sample or well 
when spraying for long periods of time. Under heated conditions using a hot plate, it is difficult to regulate 
the temperature the sample is exposed to so that it will not melt the PCL films but will not allow graphene 
solution droplets to form during spraying creating a nonhomogeneous coating of graphene materials. It is 
suggested that we translate UALR’s air spray and graphene solution protocols to our lab to improve our 
efficiency in creating prototypes of our material for the next study phase. While comparing the 
manufacturing process of this study with protocols used by UALR’s group, there is a high risk for variability 
in manufacturing when translating protocols of one lab to another. To minimize this, we manufactured our 
coatings by modifying the manufacturing protocols of UALR for this study to ensure that they are 
compatible with our lab protocols. We do not expect much variability in manufacture results due to these 
protocols being new to our lab or closely mimicking similar protocols that we utilize in our lab. 
Electrospinning process involves many variables that must be considered to tailor the specific mechanical 
and functional qualities of your fiber mesh. Altering theses variables will produce fibers with very different 
characteristics than what is expected. It was noted that the electrospinning parameters often required 
immediate changes during the spinning process in order to maintain jetting for the intended period of spray. 
These and other complications such as polymer hardening in the needle head, and solution blockages will 
have caused variations in the type of fibers that we manufactured for immunofluorescence testing. Any 
changes in the electrospinning process will alter the texture of the material surface and thus directly impact 
cell behavior on its surface as a possible explanation for unexpected cell behaviors. 
Proliferation Assays The use of soluble MTT (MTS) assays to quantitate cell viability in well conditions is 
a well-documented and popular indirect proliferation assay. However, the potential for indirect assays to 
cross react with other compounds suspended with cells such as biomaterials or for biomaterials to affect the 
cells physiology that results in false expression of MTS regents is a real concern. With graphene-based 
materials the primary toxicity concern is its ability to stimulate over production of reactive oxygen species 
in many cell lines that both directly and indirectly impacts the metabolic conditions inside the cells. This 
could provide a false positive in activation of tetrazolium salt to fluorescent formalin as an indicator for of 
good cell viability when in reality the cell is under stress. Therefore, it is suggested that direct proliferation 
assays and other indirect proliferation assays be used in conjunction with MTS to determine if a potential 
problem exist in the biomaterial [30,31]. 
The result from this study concerning viability of lower oxygen graphene materials appears to contradict 
previous studies concerning the use of graphene with lower concentrations of oxygen groups as a platform 




of graphene-based materials. In-vitro and In-vivo studies can often contradict each other due in part to the 
lack of standards for In-vitro and In-vivo towards assessing nanomaterials and the need to further understand 
the multiple forms and iterations of graphene-based materials that might play a role in other toxicity 
pathways. Graphene as a nanomaterial does not yet have a complete toxicity profile to establish with 
certainty what other toxic mechanisms it might play a role in, such as previously discussed concerning the 
possible limitations of using MTS proliferation assays on graphene and the advantages to using multiple 
assays in tandem with each other. 
While it is standard to use an appropriate immortalized cell line as a model for assessing cytotoxicity on 
biomaterial, it was felt for the purposes of determining the efficacy of our biomaterial platform to support 
ADSCs, rat ADSC were chosen as the model for assessing cytotoxicity of PCL+GO biomaterials towards 
MSC lines. However, this study could have further benefited from using cell lines intended for cell 
therapeutic delivery in neural defects with hADSC lines. This would give the study a more accurate 
assessment of our materials ability to support the proposed therapy provided by hADSC lines. While the 
two cell lines are similar in general function and role, they play in mammalian physiological systems they 
have different configurations of organelles, surface markers, and membrane channels that activate specific 
functions that might not be found in a xenogeneic cell line. Statistical Confidence in the quantitative 
assessment of Calcein AM intensity could be improved with the addition of multiple replicates instead of a 
single well set for each time point during the MTS read out. 
Immunofluorescence While a positive control material was selected to assess hADSC lines ability to adhere 
to a pro-adhesion surface, a positive control cell line to assess the positive expression S100β protein in cell 
lines where it should be highly expressed was not used. A cell line where S100β protein is highly expressed 
should have been used to determine if our primary secondary antibody protocol would work as intended. 
While previous studies have shown expression of S100β in ADSC lines it is not often certain of a positive 
expression or if the signal can even be labeled as positive. A better cell line to use and compare in tandem 
to hADSC lines would be a glial based cell line, either astrocytes, oligodendrocytes, or the most preferred 
in the case of peripheral nerves Schwann cells. 
There were difficulties in manipulating the PCL fiber mesh iterations when suspended in media solution 
for visualizing cultured cells. Films were very flimsy and the surface charge of the material as well as the 
current of the media and the presence of cells on its structure made it easy for the film to fold and collapse 
in on itself. This made it difficult to straighten out on microscope slides to visualize cell morphology and 
protein expression. An alternative method for ensuring static movement of the film when suspended in 





PCL films coated with our GO surface coatings appeared to either block or absorb DAPI blue light under 
fluorescence microscope. It has been shown that GO compounds can decrease the intensity of fluorescence 
given off from other compounds such as DAPI. This process is known as quenching compounds in 
fluorescence compounds[34]. Other alternative neural stains can be utilized on this type of graphene to 
visualize the nucleus of cells adhered to its surface such as using Propidium Iodine dead staining that 
fluoresces in the red spectrum when it binds to the nucleus of dead cells.   
2.5 Conclusion 
We have described the first initial set of In-vitro data supporting our hypothesis as a step towards further 
developing a novel synthetic 3D nerve wrap that can assist in healing critical neurotmesis injuries. Our 
assessment determined that PCL platforms of nano-fiber architecture with additional surface coating of GO 
films can support both native hADSC and hADSC pre-differentiated towards neural-like cell lineages. Both 
indirect and direct methods respectively MTS and Calcein AM/ PI live stain confirmed a higher degree of 
MSC viability when rADSC cultures were seeded on GO coatings. This was further supported when PCL 
meshes on both smooth and fiber architectures showed hADSC with characteristic morphology changes 
such as cell adhesion and spreading during the culture period when staining with cytoplasm tracker DiI. 
Distinct differences in cell morphology and S100β expression between the different media and surface 
architecture groups for each coating iteration suggests that cells were beginning to differentiate in response 
to media and surface chemical and mechanical niches. Films surfaces with fiber architecture showed a 
higher degree of organization from that of smooth film surfaces. hADSCs with long extensions would often 
align themselves to each other in parallel formation on fiber surfaces, while these same cells would often 
be spread out in chaotic fashion on smooth surfaces. Majority of GO surface coatings showed excellent 
culture of native and differentiated hADSC cultures compared to positive glass coverslips and PCL only 
films. Both GO+PCL and GO+PCL+PEG coating showed similar cell response during the culture period 
suggesting that the addition of unfunctionalized PEG surface coating dose not significantly improve or is 
detrimental to the effect that graphene has on hADSC cultures.        
The results of this study suggest that GO surface coating on PCL fiber mesh is an excellent platform for 
culturing hADSC lines. We plan to move into the next phase of In-vivo assessments using a rodent small 
animal model to create critical neurotmesis and assess the potential of our surface coated 3D wrap to assist 
in its repair. The success of these techniques used to manufacture PCL coated platforms at UALR has 
suggested plans to translate UALR’s manufacturing technology and setup to our lab at UT CVM for more 
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Chapter 3: Biometric Data Comparison Between Lewis and Sprague 





Pressure mapping systems are a commonly utilized instrument for indirect assessment of the repair of 
critical defect in small-animal models. For the purposes of our study we are interested in utilizing Tekscans 
VH4 pressure map system for assessing the degree of critical size repairs in real time during the healing 
process with rodent models. Previous studies have reported normal kinematic data from common rat 
species. However, there does not appear to be any literature that compares the normal gait pattern of 
Sprauge Dawley rats to Lewis rats using a Tekscan VH4 pressure mat system. The purpose of this study is 
to assess the gait profile of Lewis and Sprauge Dawley rats generated by Tekscan’s VH4 system to detect 
similarities and/or differences gait parameters involving both force and temporal variables to prepare for 
future critical defect In-vivo models that require careful selection of animal participants based on gait 
profile. The gait profile of 14 Lewis and 14 Sprauge Dawley rats was recorded and gait parameter data was 
normalized and compared for statistical variance between the two rodent strains. The results showed that 
the temporal and normalized force parameters were not significantly different between the two strains. 
Variation in some of these parameters were considered due to the significant difference in overall body size 
between the two strains and how each rodent act as its own independent group. For future critical size In-
vivo models, either rodent strain would be acceptable for assessing critical repair in any model that uses the 
Tekscan VH4 pressure map system since the base line gait profile recorded from both strains were found 














Animal models are the primary component in the establishment of acceptable In-vivo testing of implantable 
medical devices. Animal models have been designed to assess the standard clinical requirements expected 
of class II or III medical devices and a focused assessment of the functional properties of the device. This 
is for the purpose of studying the different variations of the device’s actual performance in a physiological 
system similar to that of humans compared to its expected or intended performance in order to prepare the 
device for consideration for clinical trials. In order for a class II or III medical device to be considered for 
clinical evaluation in human trials, the data collected from In-vivo studies must be quantifiable in order to 
be normalized to human physiologic parameters when translating from an animal model [1–3]. Biometric 
data comparing changes in gait profiles is a critical step when using animal models to study musculoskeletal 
and peripheral nerve injury. Assessment tools used in the measurement of the biometrics of locomotion are 
common tools for quantitatively assessing the quality of tissue repair [4–6]. Depending on the animal model 
and species selected, the tissues being studied to determine the performance of the device, and the tools for 
collecting and assessing gait parameters, the biometric data can be included as quantitative evidence for 
support of a class II or III device prior to human clinical trials. It is therefore important to fully understand 
the normal gait pattern for any animal species used in an animal model were gait parameter data will be 
recorded for the purposes of assessing implant performance as a prerequisite for approval to begin clinical 
trials in humans. 
While the types of animal species used and the specific tissues assessed in critical size defect models has 
changed by a small margin, the tools and techniques used to assess gait patterns and report quantitative data 
has markedly improved [7–9]. This is due, in part, to the inclusion of novel technologies that can more 
precisely and accurately detect specific gait parameters with minimal background noise, the augmentation 
of previous methods by combining different technologies together creating instruments capable of 
producing a more extensive gait profile, and the increased practice of using exogenous gait biometric data 
from previous tissue repair studies as an acceptable control standard for quantifying implant performance 
In-vivo. Rats are one of the most common animals used in critical defect models for preclinical testing of 
class II and III medical devices [10–12]. As the instrumentations for assessing gait parameters continues to 
develop new technologies, it is important that normal gait parameters of different species of rats are 
determined to provide data upon which to plan experiments. It is also valuable to compare normal gait 
biometrics between different species of rats that use similar gait assessment tools in order to evaluate 
differences among species used for specific defect models. This is especially relevant for biometric tools 
that find significant differences in the gait parameters between different strains of rats, where one species 




predictable gait pattern could have a greater advantage in profiling tissue repair in specific critical defect 
models In-vivo. 
Recently, pressure sensing mat technology has been developed as a more accurate and precise tool for 
quantifying gait [13–15].We aimed to utilize a commonly used pressure sensing mat tool to measure the 
kinematic and timing variables in both the forelimb and hindlimbs of two species of rats. Studies that have 
utilized the VH4 system have reported excellent calibration reliability of the 5101 sensors in In-vivo studies 
of 1.2–4.4%, well within the established acceptable cut-off range of 5%. A previous study also reported 
this as an acceptable range when reporting sensor reliability ranges of 3–4% [16]. Two of the most common 
rat species used in In-vivo critical defect testing are Sprague Dawley and Lewis rats [17,18]. While previous 
studies have reported normal kinematic data from these rat species, there does not appear to be any literature 
that compares the normal gait pattern of Sprauge Dawley rats to Lewis rats using a pressure mat system 
[19–22]. In this study we will be comparing the gait parameters between Sprauge Dawley and Lewis rats. 
The type of data output from pressure mat systems concerns both temporal and force gait data. Temporal 
data analyzed in this study includes stance time (how long each limb makes contact with mat), swing time 
(the time it takes between two hits on the mat with the same hindlimb), stride time (the time it takes between 
right forelimb and left hindlimb to make contact with the mat at the same time as well as the opposite limb 
pattern), stride length (distance between right forelimb and left hindlimb as well as its opposite limb pattern) 
stride velocity, stride acceleration, and limb surface area coverage. Force data assessment includes the limb 
forces generated on the mat with respect to pressure difference, normalized force data to the body weight 
of each rodent, impulse force in each hindlimb. 
We hypothesized that the normal walking gait motion between the two species would be similar. The 
objective is to comparing the gait parameters between Sprauge Dawley and Lewis rats. The type of data 
output from pressure mat systems concerns both temporal and force gait data. Temporal data analyzed in 
this study includes stance time (how long each limb makes contact with mat), swing time (the time it takes 
between two hits on the mat with the same hindlimb), stride time (the time it takes between right forelimb 
and left hindlimb to make contact with the mat at the same time as well as the opposite limb pattern), stride 
length (distance between right forelimb and left hindlimb as well as its opposite limb pattern) stride velocity, 
stride acceleration, and limb surface area coverage. Force data assessment includes the limb forces 
generated on the mat with respect to pressure difference, normalized force data to the body weight of each 
rodent, impulse force in each hindlimb and its normalized version to the rodent bodyweights, and the peak 
pressure generated in each hindlimb. The system is also capable of comparing specific limbs to each other 
as a ratio profile for maximum force generation, stance time, stride time, stride length, and stride velocity 




limbs on the right side of rodent to all limbs on the left side, right forelimb to left forelimb, and right 
hindlimb to left hindlimb.  
3.2 Methods 
The study was approved by the Institutional Animal Care and Use Committee (IACUC) at the University 
of Tennessee, Knoxville (IACUC# 2574-0318). Lewis and Sprague Dawley rats were selected for use in 
the study of gait biometrics. Sprague Dawley and Lewis rats used in this study were eight-week old males 
(n=14, each) and allowed to acclimate to their environment for one week before gait assessment. Animals 
were directed to walk two passes on the pressure mat during each testing period before the testing began in 
order for the animals to get familiar to the mat and become comfortable with handling and being directed 
across the mat.      
3.2.1 Pressure Sensing Mat Specifications  
Gait patterns were analyzed using a pressure sensor mat (Tekscan VH4, Tekscan, Boston, MA). This mat 
is composed of four 5101 high-resolution pressure sensor matrix grids layered in series to each other. The 
sensing area uses rows and columns of sensels and converts the change in electrical resistance to a force 
based on calibration to known applied weight. Each sensor has a grid of 44 columns and 44 rows (11.2 cm 
x 11.2 cm) of sensels, creating 176 sensel columns x 44 sensel rows for a total area of 11.18 cm x 44.7 cm 
(499.75 cm2) with a 0.127-cm gap between sensels in each row and column. The total grid has 7,744 sensels 
at a density of 15.5 sensels/cm2. The sensors/handles were aligned to place the origin (0,0) in the upper left 
corner of the sensel grid [23]. For the purpose of this experiment, The gait testing unit was modified to 
include a tinted Plexiglas tunnel (width 17.0 cm, height 17.0 cm, length 44.7 cm) and a Styrofoam side wall 
(width 2.54 cm, height 2.54 cm, length 44.7 cm) for the purpose of guiding the rats across the mat and to 
insure that the rats remained in the sensel area so that  the rats would perform normal walking gait patterns 
across the entirety of the mat. This minimized false data recordings from animal miss-steps on the edges or 
outside the sensor matrix area (Figure 3.1).  
The pressure sensing mat was calibrated using a phantom device designed to support a known mass (2,006.8 
g; 4.42 lb.; 19.7 N). The instrument was programmed to record gait parameters at a sample rate of 50 
frames/sec, with start and stop recordings being manually controlled. Calibration accuracy was tested by 
comparing five repeated measures of the phantom weight. Tekscan software records the raw data of each 
gait variable as an average mean value for each trial walk in an ASCII file format. Each limb must record 
at least 3 footfalls (“hits”) on the mat to calculate an average value, otherwise the software will record an 





Figure 3.1 Tekscan VH4 Pressure-mat system setup.  
Note: Testing apparatus consists of a tinted Plexiglas tunnel (A). The tunnel is positioned over the Tekscan pressure mat aligned to Styrofoam 
borders placed at the edges of the sensel area (B). Four sensors (VH1–4) connect the four 5101 sensors to the Tekscan mat. 
 
3.2.2 Gait Testing Protocol 
Calibration of the pressure sensors was carried out before each use of the device. Each rat was weighed 
using a digital scale before starting walk trials on the mat. The rats were released on either side of the 
pressure mat facing the open end of the transparent Plexiglas tunnel centered over the sensel area on the 
mat. The tunnel was designed with dimensions that encompassed the Styrofoam walls attached to the mat 
without making contact with the sensel area. After the rats had been acclimated to their environment for at 
least 1 week and body weights were recorded, the rats were positioned and held by the operator at either 
end of the tunnel openings and released when the test was initiated by manually starting the recording 
procedure in the software by the operator. The animal then traversed the length of the tunnel until they 
reached the other end at which time the recording was stopped manually for either a successful trial or an 
incomplete trial as determined by the software operator.  
Criteria for a successful walk across the mat was determined if the rats were able to walk continuously from 
one end of the mat to the other with minimal to no pause in gait motion and at least three strikes were 
detected for each limb as confirmed by reviewing video recording of the measured biometric data on the 
software. All data recorded for the gait parameters were average values from each successful trial. The 
procedure was repeated for each animal until 2 successful trials were achieved, giving a total of 28 data sets 







as recorded by the sensels and identified as either the right forelimb (RF), left forelimb (LF), right hindlimb 
(RH), or left hindlimb (LH) as a whole for the trial.  
A video camera was attached to a strip located directly above the Plexiglas tunnel and synced to the gait 
profile to capture the motion of the animals as they walked across the mat to observe the subject’s behavior 
and match the limbs with the corresponding limb strikes in the gait profile. The operator had to use video 
synchronization in order to identify any software selection of the wrong limb strike box and when it the 
software was unable to discern multiple limb strikes at a single location during the trials due to ipsilateral 
forelimb and hindlimb contact which often overlap each other. This made it necessary to manually correct 
boxes by following the subject’s motion on both the camera and gait force profile for corrected gait 
assessment (Figure 3.2). 
 
 
Figure 3.2 Tekscan software display.  
Note: A: Example gait force profile during the subjects walk from right to left. Visual display of right forelimb (red), left forelimb (green), right 
hindlimb (pink), and left hindlimb (blue) contact sensor boxes is represented as the summation of sensels activated and their corresponding limbs 
recording location on the mat, time, and gait variables. B: Graph of force vs. time for the example gait profile of force peaks with their respective 










Gait temporal variables measured included average stance time, swing time, stride time, stride length, stride 
velocity, and stride acceleration based on the location of the limb strikes relative to the sensel area and 
another subsequent limb strikes. Contact variables included contact area derived from the maximum 
number of sensels loaded. Force generation parameters included contact force, impulse force, and contact 
pressure derived from the maximum sensor readings at the time of impact. Contact pressure, impulse force 
and contact force were normalized to the weight of the animals on the date of testing (average value divided 
by body weight). Time variables (stance time, stride time, stride length, and stride velocity) and maximum 
force were normalized to specific limb orientations (forelimbs to hindlimbs, left side limbs to the right sided 
limbs, left forelimb to right forelimb and left hindlimb to right hindlimb) and compared for statistical 
significance. 
3.2.3 Statistical Analysis  
All successful trials were included from each rodent group. Analysis of variance was used to compare all 
28 data sets per rodent group as a means comparison for each gait variable. Two-way analysis of variance 
for comparisons between the groups followed by Bonferroni’s post-hoc analysis. Significance was set at P 
≤ 0.05. 
3.3 Results 
3.3.1 Normal Gait Assessment 
All 28 rodent subjects from the Sprague Dawley (n=14) and Lewis (n=14) rat groups completed two 
successful walk trials. This resulted in a total of 28 successful gait trials per group, giving a total of 56 data 
sets to assess mean values of gait parameters for rodent groups. The body weight of each rat was recorded 
before beginning trials. Significant difference was detected in the initial body weight of the rat groups, with 






Figure 3.3 Mean Body weight distribution between Lewis and Sprauge Dawley Rats 
 
 Note: ANOVA analysis *P ≤ 0.05 
 
 
3.3.2 Gait Analysis: Ratio Temporal Parameters 
The ratio means values indicate the degree of variance between different limbs for specific temporal 
variables (Figure 3.4). The mean and standard deviations applicable for each gait variable assessed are 
presented as follows: Sprague Dawley Rat (SD), Lewis Rat (LR), Stance Time forelimb/hindlimb (Stance 
TF/H), Stride Time forelimb/hindlimb (StrideTF/H), Stride Length forelimb/hindlimb (StrideLF/H), Stride 
Velocity forelimb/hindlimb (StrideVF/H), and Maximum Force forelimb/hindlimb (MFF/H), Stance Time 
Left side/Right side (Stance TL/R), Stride Time Left side/Right side (StrideTL/R), Stride Length Left 
side/Right side (StrideLL/R), Stride Velocity Left side/Right side (StrideVL/R), and Maximum Force Left 
side/Right side (MFL/R), Stance Time Left forelimb/Right forelimb (Stance TLF/RF), Stride Time Left 
forelimb/Right forelimb (Stride TLF/RF), Stride Length Left forelimb/Right forelimb (Stride LLF/RF), 
Stride Velocity Left forelimb/Right forelimb (StrideVLF/RF), and Maximum Force Left forelimb/Right 
forelimb (MFLF/RF), Stance Time Left hindlimb/Right hindlimb (Stance TLH/RH), Stride Time Left 
hindlimb/Right hindlimb (StrideTLH/RH), Stride Length Left hindlimb/Right hindlimb (StrideLLH/RH), 




































Figure 3.4 Ratio temporal and force parameter values  
Note: ANOVA analysis. *P ≤ 0.05             
 
Table 3.1 Ratio values for normalized temporal parameters  
Species StanceTF/H StrideTF/H StrideLF/H Stride VF/H MFF/H 
      
SD 0.77±0.16 0.97±0.155 1.06±0.166 1.12±0.25 0.83±0.2 
LR 0.79±0.16 1.02±0.08 1.03±0.101 1.02±0.1 0.76±0.09 
      
Species Stance TL/R Stride TL/R Stride LL/R Stride VL/R MFL/R 
      
SD 1.00±0.18 1.02±0.16 0.99±0.11 0.98±0.16 0.95±0.21 
LR 0.97±0.13 0.988±0.10 0.99±0.105 1.0±0.08 0.96±0.12 
      
Species Stance TLF/RF Stride TLF/RF Stride LLF/RF Stride VLF/RF MFLF/RF 
      
SD 0.97±0.21 1.08±0.26 0.98±0.17 0.96±0.28 0.894±0.21 
LR 0.97±0.32 0.98±0.13 0.98±0.1 1.01±0.13 0.94±0.204 
      
Species Stance TLH/RH Stride TLH/RH Stride LLH/RH Stride VLH/RH MFLH/RH 
      
SD 1.06±0.34 1±0.24 1.01±0.17 1.06±0.28 1.02±0.28 
LR 1.02±0.26 1±0.15 1±0.17 1±0.13 0.99±0.13 
Note: Stance Time, Stride Time, Stride Length, Stride Velocity, and Maximum Force comparative analysis based on limbs. The closer the 





















































(sec) Cycles_min (sec) 
       
SD 14.43±2.3 1.88±0.86 30.47±5.64 19.85±9.8 0.62±0.233 110.43±39.5 
LR 17.93±1.94 2.04±0.57 37.32±3.67 19.85±6.2 0.5±0.104 125.3±25.45 
       
 
 
Table 3.3 Values based on specific limbs for both species. 











        
LR LF 0.30±0.142 0.2175±0.076 0.493±0.112 9.37±1.41 20.27±6.44 -2.05±26.93 
 LH 0.4±0.15 0.129±0.05 0.49±0.119 9.22±1.48 19.8±5.57 2.81±36.63 
 RF 0.32±0.109 0.212±0.052 0.51±0.109 9.62±1.27 20.21±6.30 1.15±24.38 
 RH 0.408±0.184 0.136±0.23 0.491±0.099 9.34±1.42 19.88±5.64 14.8±35.85 
        
SD LF 0.356±0.133 0.295±0.174 0.629±0.235 10.58±2.29 19.73±9.63 5.93±25.34 
 LH 0.499±0.2 0.181±0.077 0.63±0.275 10.54±2.28 19.3±8.08 -8.95±20.7 
 RF 0.368±0.13 0.249±0.16 0.60±0.257 10.96±2.24 21.73±10.44 5.12±32.47 
 RH 0.486±0.2 0.178±0.075 0.651±0.252 10.33±1.88 18.94±10.01 13.4±35.93 




(%) MF (gr) 
Impulse_BW 





         
LR LF 61.93±10.53 133.9±29.83 10.86±3.06 23.64±8.25 47.7±9.74 0.508±0.08 1.3±0.353 
 LH 84.71±9.7 183.6±37.17 20.09±7.86 44.46±22.52 55.53±9.74 0.611±0.1 1.46±0.26 
 RF 67.02±10.55 144.3±26.82 12.2±3 26.57±8.49 49.04±7.9 0.515±0.07 1.35±0.203 
 RH 86.55±10.52 187.3±35.34 20.5±6.27 44.8±17.1 56.2±10.1 0.633±0.12 1.441±0.253 
         
SD LF 63.64±13.17 161.0±33.93 12.7±4.54 31.93±10.73 51.75±9.56 0.568±0.11 1.127±0.203 
 LH 84.48±15.0 215.9±43.05 24.57±9.53 62.96±25.73 61.4±6.96 0.704±0.14 1.215±0.174 
 RF 74.83±19.3 189.8±45.03 14.18±5.45 35.86±12.66 56.46±9.95 0.611±0.112 1.225±0.225 
 RH 85.29±16.63 217.9±46.1 24.6±12.14 63.11±32.71 64.07±8.45 0.726±0.133 1.19±0.214 








3.3.3 Gait Analysis: Force and Temporal Parameters 
Force and temporal parameter values specific to the four limbs that make up the gait profile of each animal 
group (Figure 3.5). Mean variance analysis showed that there were no significant differences for both the 
Sprague Dawley and Lewis rat groups in the stride velocity and stride acceleration temporal parameters for 
each limb. The analysis also determined that the normalized maximum and impulse forces in the groups for 
each limb were statistically similar. Stride length, impulse force, maximum force, contact area, and 
normalized pressure showed statistical differences between the groups for each limb tested. Swing time, 
and stride time showed statistical differences between the groups for the hindlimbs and the left forelimb 
while the right forelimb showed no significant difference. The stance time showed a significant difference 
for the left hindlimb only. The maximum peak force showed significant differences for all limbs except the 
left forelimb.  
 
 
                    
Figure 3.5 Analysis of variance of gait variables 
Note: Two-way ANOVA Bonferroni’s post-hoc and Tukey’s grouping analysis. Statistical comparison of values between Lewis Rats (LR) and 
Sprague Dawley rats (SD), subcategorized by left forelimb (LF), right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). All values 
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Gait parameters recorded from left and right hind limbs were also assessed for mean variance grouping 
between the limbs for each rat group to determine how similar the mean force and temporal values are 
compared to each limb. In the Lewis group stride time, stride length, stride velocity, stride acceleration, and 
normalized pressure in each limb were found to be statically similar to each other. Swing time, maximum 
force, normalized maximum force, impulse force, normalized impulse force, and contact area showed 
statistical differences between the forelimbs and the hindlimbs with the hindlimb mean values having a 
higher value compared to the forelimb.  Maximum pressure and stance time mean variables for Lewis limbs 
were grouped based on their statistical mean variance from each other.  
Similar to the Lewis group, the Sprague Dawley group stride time, stride length, stride velocity, stride 
acceleration, and normalized pressure in each limb were found to be statically similar. Stance time, impulse 
force, normalized impulse force, and contact area showed statistical differences between the forelimbs and 
the hindlimbs with the hindlimb mean values having a higher value compared to the forelimb. Swing time, 
maximum pressure, maximum force, and normalized force mean variables for Sprague Dawley limbs were 
grouped based on their statistical mean variance from each other.  
Mean temporal parameters concerning gait distance and gait cycle time were found to be significantly 
different between the two groups, while all other variables cycle min, gait velocity, gait time, and number 
















        
 
Figure 3.6 Mean temporal parameter values 
 



















































































































To our knowledge, this is the first study to compare the gait pattern between Sprague Dawley and Lewis 
rat species using the pressure mapping system. We have identified specific differences in the gait pattern 
between these rat species that might be a factor to consider when choosing appropriate rodent species for 
critical defect models. Large variances were detected in both the Sprauge Dawley and Lewis rat groups 
when comparing the forelimbs to the hindlimbs for variables concerning the maximum force and stance 
time. All other limb iterations and variables assessed showed mean values with variances that did not exceed 
deviations greater than 0.12, indicating small differences in gait temporal values between the limbs of the 
rats. ANOVA analysis of each gait variable was assessed between the animal groups, these results are 
identified in Table 3.4.  
 










       
LF 0 1 1 1 0 0 
LH 1 1 1 1 0 0 
RF 0 0 0 1 0 0 




(%) MF (gr) Impulse_BW (%) 
Impulse 





        
LF 0 1 0 1 0 1 1 
LH 0 1 0 1 1 1 1 
RF 0 1 0 1 1 1 1 
RH 0 1 0 1 1 1 1 
        
Note: Sprague Dawley rats (SD), subcategorized by left forelimb (LF), right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). 1= 







Variables concerning speed, acceleration and normalized forces generated in each limb of Sprague Dawley 
and Lewis rats are expected to have similar values and variations given the conditions of the rat population 
studied. The analysis also showed expected differences between the groups concerning the unadjusted 
impulse force, maximum force, contact area, stride length, and adjusted pressure values detected in each 
limb. The temporal parameters concerning stance time, swing time, and stride time were unexpected in that 
the results indicated similar swing and stride times for the right forelimb yet significant difference in the 
stance time for the left hindlimb between the two groups. The most likely cause for these differences 
between the two groups is the presence of some rats with gait patterns that favor a particular limb over the 
others, creating an uneven gait kinematics and locomotion during normal gait motion. This theory is 
corroborated when grouping the mean values of the limbs for each group (Table 3.5 and Table 3.6) which 
showed swing and stances times which had different mean grouping profiles between the limbs for each 
group indicating partial unevenness to the normal gait of these groups. This has been confirmed from 
previous studies that have noted similar observations in the normal gait pattern of rodents. 
 














       
LF 1 1 0 0 0 0 
LH 1, 2 2 0 0 0 0 
RF 1, 2 1 0 0 0 0 
RH 2 2 0 0 0 0 
       
Lewis  
MF_BW 











        
LF 1 1 1 1 1 1 0 
LH 2 2 2 2 2, 3 2 0 
RF 1 1 1 1 1, 2 1 0 
RH 2 2 2 2 3 2 0 
        























       
LF 1 1 0 0 0 0 
LH 2 2 0 0 0 0 
RF 1 1, 2 0 0 0 0 




(%) MF (gr) 
Impulse_BW 




(cm²) Adj_Pr (g/cm²)/BW 
        
LF 1 1 1 1 1 1 0 
LH 2 2 2 2 2, 3 2 0 
RF 1, 2 1, 2 1 1 1, 2 1 0 
RH 2 2 2 2 3 2 0 
        
Note: Right forelimb (RF), and left hindlimb (LH), and right hindlimb (RH). 1, 2, 3= individual groups for mean variance, 0= similar mean 
variance group 
 
Forward motion variables such as velocity and acceleration were consistent between both groups, including 
the additional analysis of individual limbs regarding these variables. This would indicate that the motion of 
each of the limbs of the rats was the same for both groups. Due to the difference in animal size between the 
groups, swing time and stride length variables were statistically different between the two groups, where 
the Sprauge Dawley rats showed greater stride length and swing time than the Lewis rats [24]. This also 
explains why the Sprague Dawley group had on average a lower mean value of stances number, gait length, 
and gait time compared to the Lewis group. As expected, normalized maximum and impulse forces were 
consistent between both groups. Meaning that the force generated in each limb during both deceleration 
and acceleration of the limbs on the mat were the same between both groups when normalized to the weight 
distribution of the rats in each of their respective limbs. This was further confirmed when grouping the 
mean values of the limbs for each group, which showed statistically similar stride velocity and acceleration 
for each limb while normalized force and contact area values remained statistically different between 
forelimbs and hindlimbs. Previous studies have used rodents as a control group for normal gait motion and 
have described this gait pattern were the hindlimbs will support more of the rodent’s weight compared to 
the forelimbs due to the unequal distribution of the rodent weight across the body frame from the front end 
to the back end [7,21]. This also explains why the stance time variable has a large variance between the 
forelimbs and hindlimbs for both rodent groups, as the greater weight supported by the hindlimbs needs 
more time to stabilize and propel the body forward during normal gait motion. This is why during normal 
gait motion in rodents the hindlimbs are considered more responsible for producing forward motion, while 





In summary, we highlighted specific differences in the gait pattern between Sprague Dawley and Lewis rat 
groups using the VH4 Tekscan pressure mapping gait system. This in an effort to establish a control 
standard gait model to assist in selecting appropriate animals for critical defect models where animal gait 
biometric data is relevant and the tool for assessing gait patterns is similar to Tekscan’ s VH4 model. We 
have shown for the first time, comparative quantitative assessment of normal gait patterns in Sprague 
Dawley to Lewis rats using Tekscan’ s VH4 pressure-map system. Our results concerning normalized force 
and stride velocity/acceleration variables shows that both groups maintained statistically similar weight 
distributions and forward motion in each limb during normal walk patterns. Unadjusted variables 
concerning contact area, force and stride length showed significant differences between the two groups for 
each limb and fore limbs from each group having significantly different values compared to the hind limbs. 
We also detected irregular patterns in the swing, stride, and stance time variables between the two groups 
which we attribute to uneven gait motion during the trial due to favoring or odd sensation from one or more 
limbs.  
This data would suggest that the gait pattern for Sprague Dawley rats are statistically similar to that of the 
gait pattern of Lewis rats when using Tekscan’ s VH4 model pressure mat system. Careful consideration 
must be taken for possible variations in the temporal data due to specific rodent biometric specification, 
asymmetrical gait patterns due to limb sensations or favoritism, and the rodent’s behavior and degree of 
training prior to testing on the pressure mat.  This would indicate that for the purposes of collecting gait 
biometric data as a quantitative assessment of tissue repair in critical size defect models that the use of 
either Sprauge Dawley or Lewis rat normal gait patterns might both be used interchangeably as acceptable 
positive gait control models. Certain limitations to this study should be considered such as a much-focused 
set of rodent specifications that might overlook other biometric variables that have a larger impact on 
normal rodent gait patterns such as male vs female and other rodent species, the time and form of training 
and conditioning prior to test, ease and difficulty to house and handle, and potential physiological changes 
brought on by stress or pathogens. Comparison of the Tekscan VH4 model results with other highly 
sensitive pressure mat systems results might be prudent to help establish control rodent gait patterns for 
other commonly utilized gait assessment tools. The statistical power of this study could also be improved 
by amending the number of trials performed by each rat to a higher number than 2 or by increasing the 
number rodents acquired for the study.  
Moving forward with assessing the performance of our neural wraps in a sciatic nerve defect model In-vivo, 




[25]. While both Lewis and Sprague Dawley rats are considered active rodent strains suitable for gait 
analysis for assessing nerve repair, it is suggested that Lewis rats are used as the subjects in critical nerve 
defect models over other alternative rodent strains due to minimal occurrence of autotomy behavior after 
an extended period post transection of the sciatic nerve gap. This is supported by previous studies that have 
highlighted the physiological behavior changes in different rodent strains after induction of critical size 
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Chapter 4: Critical Nerve Defect Model using Lewis Rat Subjects to 
























The successful establishment of PCL+GO platforms and the successful In-vitro testing for biocompatibility 
towards adipose derived MSC and ability to support neural stimulated hADSC culture has provided the first 
round of data that supports this material as a potential biomaterial candidate for creating neural wraps to be 
used in the repair of critical neural defects. In this study, we have established a rodent model using Lewis 
rats to simulate a critical nerve defect and determine the potential of this material with hADSC cultures is 
at assisting in the repair of critical nerve defects In-vivo. 24 total Lewis rats were separated into 4 
independent treatment groups.  Treatment was left to provide its intended therapy for 12 weeks before being 
removed for histology assessment of the repair. Gait assessment of the rodent’s gait pattern was also 
collected using a Tekscan pressure mat system as an indirect assessment for return of neural function. 
Results of our gait analysis indicate a significant deviation from normal rodent gait patterns after creating 
the neural defect in rats as expected, however data could not conclude if nerve function was beginning to 
return at the defect site by 12 weeks repair. Histology sections of the neural wraps at 12 weeks show new 
tissue growth present inside the neural wrap tubing with tissue growth expanding across the material 
towards the distal section of the defect. Staining shows that new tissue has similar characteristics to the 
tissue found in native peripheral nerves in terms of tissue layering and organization. However, we cannot 
yet fully identify what the new tissue is until a more specific set of staining protocols are used. Most likely 
these stains will search for tissue that we expect to make up a significant component of the new tissue that 
is growing such as axon, myelin, and Schwann cell specific stains. From this study we determined that this 
material has potential to grow new tissue at critical nerve defects while remaining intact for up to 12 weeks 
In-vivo. The effectiveness of the material to regenerate new neural tissue, or how effective the addition of 
hADSC therapies is in repairing the defect remains unknown and is the center of new studies being 











4.1 Sciatic Nerve Transection Model  
4.1.1 Introduction 
Neurotmesis is one of the most damaging forms of peripheral neuropathy that affects approximately 3 % 
of trauma patients around the globe. Severe forms of neurotmesis involves significant gaps (>2-3 cm) along 
peripheral nerve sections that often require surgical intervention to successfully repair. Currently, the gold 
standard for repair of severe neurotmesis is the use of autograft nerve segments taken from a different area 
of the patient were the nerve type, diameter size, and length are similar to the nerve gap. The limitations of 
this method are well known and the expected degree of repair from such technique are quite varied which 
has opened to discussions of finding alternative methods of tissue repair. The use of scaffolds to regenerate 
damaged peripheral nerve presents a possible solution to healing severely damaged peripheral nerve 
segments. For peripheral nerve injuries a preferred scaffold implant is one that can support the damaged 
nerve at the wound site as well as stimulate and guide the growth of new peripheral nerve tissue through 
the scaffold.  
In our previous study, we assessed the cytocompatibility of our novel biomaterial to support hADSC in a 
combined therapeutic approach to assist in peripheral nerve repair using manufacturing techniques 
developed thru our collaboration with the University of Arkansas Little Rock (UALR) Nanotechnology 
group. We have also provided the methods and resources to assess the compatibility of novel biomaterials 
developed by UALR intended also for assisting in the repair of severe neurotmesis injuries. All iterations 
regarding the development of these candidate neural scaffolds have been assessed in vitro using MSC 
culture systems. Previous In-vitro analysis of cytotoxicity and stability as a cell platform have been assessed 
via cultures of established Mesenchymal stem cell lines (hADSC and rADSC) by evaluating cell 
proliferation, viability. We also have assessed the biomaterials potential to guide MSC lines in vitro towards 
neural-like lineages when artificially increasing cAMP messenger proteins to guide differentiation of MSCs 
towards a neural-like phenotype by evaluating the changes in expression intensity of proteins present during 
neural differentiation such as S100β.  
We determined that Electrospun PCL fiber meshes surface coated with GO nanomaterials were capable of 
supporting hADSC lines in both their undifferentiated form and their differentiated states towards neural-
like phenotypes. It is suggested from these results that In-vivo testing is the next reasonable step to 
determine the scaffolds ability to stimulate nerve regeneration, re-establish functional activity of the nerve, 
and return to function of tissues innervated by target nerves. This work must be done using animal models 
of induced nerve defects so that the biological response can be assessed [1–3]. These in vivo models also 




we modified the films into 3D neural wrap prototypes to be assessed In-vivo for their potential in assisting 
in actual nerve repair. We utilized a rat sciatic nerve model in which a segmental defect is made in the 
sciatic nerve of rats which is then repaired with our 3D neural wraps consisting of PCL fiber meshes 
modified with GO surface coating. 
The sciatic nerve defect model utilizing rodents is the most commonly used small-animal model for 
evaluating neural repair. The model consists of transecting a segment of the animal’s peripheral nerve on 
either the left or right hind limb. The segment having a gap that is considered a critical defect based on the 
species and size of the animal subject. The peripheral nerve gap is then connected by an open-end 
cylindrical conduit/wrap biomaterial or a peripheral nerve graft that is surgically aligned to the distal and 
proximal ends of the gap with minimal tension and impairment to new growing native tissue. The animal 
subject remains under observation until either partial repair or complete repair of the nerve gap is reached 
in order to assess the quality of tissue growth. This time variable is dependent on the animal species and 
the size of the nerve gap based on the expected rate of peripheral nerve growth to span the defect. The most 
common methods for evaluating the return of normal peripheral nerve function can use both direct 
(electrophysiology, muscle mass, histochemical staining) and indirect (gait analysis, pain sensation) 
methods. Multiple methods used in tangent with each other can assess the presence of new nerve tissue 
growth and whether it is functional.     
Rodents are a validated, extensively published, and common model used in evaluating neural conduit or 
wrap In-vivo cytotoxicity and regenerative capability of these biomaterials due to their relevant neural 
physiology, ease of handling, small size and affordability, and the shortened time required to reach end 
points successful peripheral nerve healing. There are studies that have attempted to standardized the sciatic 
nerve model by controlling for specific variables present in the rodent subjects to determine the optimal 
rodent variables to use in the sciatic nerve model. Such variables include species, age range, sex, rodent 
body dimensions, and breeding vendor in an attempt to improve the precision of end-result data and quality 
of tissues extracted for assessment. Studies have also noted asymmetrical or abnormal behavior in rodent 
species in response to transection of their sciatic nerves including differences in normal gain motion. One 
such behavior is self-mutilation or atotomy at limbs affected by the transection of the sciatic nerve. The 
current consensus in the appropriate animal subjects to use for the sciatic nerve model are Lewis rats due 
to minimal occurrence of atotomy behavior after prolonged exposure to sciatic nerve transection compared 
to other common rodent species used in this model (Sprauge Daweley, Wistar). Male rodents have reported 
greater lengths in newly regenerating peripheral nerves compared to female, while the rate of nerve 




populations. It is suggested that healthy male Lewis rats that fall within the demographic of 8 to 12 weeks 
old is the best subjects for this model.      
The objective of this study is to assess the In-vivo potential of neural wrap designs to assist in healing 
critical neurotmesis defects through changes in gait parameters, and histochemical staining assessment. It 
is hypothesized that PCL biomaterials enhanced with the addition of GO, or Gold-nanorod thin film surface 
coatings with the addition of hADSC therapy can support the growth of new peripheral nerve in an In-vivo 
system. At 12 weeks post-repair of critical defect, we expect that new peripheral nerve will span the defect 
gap and reach the distal stump by growing along the scaffolding designs. Attention to new tissue 
organization compared to native peripheral nerves and the distance of new tissue growth thru the nerve 
scaffolding are critical for this assessment. Results of these studies will guide further research to improve 
the designs of these nerve scaffold prototypes and determine the functionality of any potential nerve tissue 
growth on these scaffolds. The end result is to create a peripheral nerve scaffold that is capable repairing 
severe neurotmesis cases in both humans and animals. If we can design a biomaterial platform that meets 
or exceeds the quality of repair achieved in autologous neural grafts, we can begin the process of 
establishing clinical trials for assessment in humans which will hopefully result in a successful translation 
of our patent into the neural graft market.   
4.2 Methods 
The study was approved by the Institutional Animal Care and Use Committee (IACUC) at the University 
of Tennessee, Knoxville (IACUC# 2574-0318). 24 Lewis rats were selected for use in the study of gait 
biometrics and histology assessment. Lewis rats used in this study were eight-week old males and allowed 
to acclimate to their environment for one week before the surgery date. Animals were organized into 6 
independent groups as follows: Group 1- control only (sciatic nerve defect with no treatment of the defect, 
Group 2-3 represented electrospun PCL wraps with GO surface coating. and electrospun PCL wraps with 
GO surface coating pre-cultured with hADSC lines. Group 4- Autologous nerve graft. Each group included 
a sample size of n=6. Lewis rats were subjected to critical size neurotmesis nerve injury to their sciatic 
nerves as described in previous similar nerve models [1,4]. Animals in each group were maintained for up 







4.2.1 Electrospinning  
The creation of 3D PCL meshes of nanofibrous architecture was performed with the same solution and 
electrospinning parameters as discussed in Chapter 2 methods section (pg. 6) with modifications in the 
parameters including changing the voltage applied to 15 kV charge and altering the needle tip-to-collector 
distance setting to 6 inches to create PCL fiber meshes of greater rigidity and easier to manage when wetted 
in cell culture media. To create a thicker PCL nanofiber mesh deposit on the collector mandrel, the solution 
was left to spin for 4 hours which used a total of 4 ml of spinning solution per spin which created a projected 
film thickness of approximately 0.01 mm. The entire PCL mesh was removed from the collector plate and 
cut to the dimensions of 9cm x 12cm sections. The sections were attached to a 24-culture well lid using 
tape and pre-sterilized under UV sterilization for 4 hours prior to air spraying GO solutions onto the surface 
of the mesh. GO solution was prepared under the same parameters as discussed in Chapter 2 (pg. 5). GO 
solutions was bath sonicated for 30 min to evenly disperse graphene oxide films in solution that have settled 
to the bottom of the container after 24 hours or more in storage before being used to coat the materials. 
Under fume hood conditions, 10ml of GO solution was used to coat the surface of PCL fiber meshes using 
air spray technique on hot plate set to between 45-55°C. Solutions were sprayed at 21 psi. PCL meshes was 
removed from 24 culture-well lid and placed into sterile glass dishes with glass cover lids. Under cell-
culture sterile hood conditions, PCL GO coating fiber mesh sections were cut to dimensions of 12mm x 
6mm sections as appropriate to span the expected sciatic nerve defect length with a 1 mm margin of error 
for attaching the proximal and distal sections. 
4.2.2 Animal Surgery  
Prior to surgery, all neural wrap prototypes were UV sterilized for 4 hours under cell culture sterile hood 
prior to culturing cells. 24 hours prior to implanting the PCL nerve wraps into rodent subjects, hADSC cell 
lines used in the previous Chapter 2 In-vitro study were cultured onto the surface of nerve wraps that were 
placed into 30mm diameter sterile non-tissue culture polystyrene wells. 1*106 total hADSC cells were 
seeded at a concentration of 1*106 cells/ 200μl DMEM-F12 stem cell culture media to the surface of nerve 
wraps. The cells were left to adhere to the surface of the nerve wrap for 3 hours before adding an additional 
800μl of DMEM-F12 culture media to the well to support the cell lines for the remaining 21 hours in culture 
period. To determine if hADSC cell lines successfully adhered to the surface of nerve wraps in 24 hours 
post seeding, DiI staining was used to track the remaining viable cells found on the surface of the nerve 
wraps. If the nerve wraps showed a majority of its surface covered with hADSC cell lines with characteristic 
stretching and spreading indicative of cells successfully adhered to biomaterials the wrap remained in 
incubation until needed for implantation. All films were transferred into sterile wells filled with sterile 




All subjects were initially weighed and injected with 0.03 mg/kg; subcutaneous injection of buprenorphine 
just before prepping for surgery. Under isoflurane anesthesia, all rats were positioned into lateral 
recumbency and prepped for surgery by shaving the right hind leg and sterilized using isopropanol and 
iodine solutions. A skin incision of 3 cm was made longitudinally to the posterior aspect of each thigh, from 
the greater trochanter to the knee. Blunt dissection of the gluteus maximus and biceps femoris muscles will 
expose the sciatic nerve directly underneath. A critical size nerve defect in rats is approximately 10 mm 
which was made by removing a segment of the sciatic nerve. The defect was repaired using our PCL fiber 
mesh coated with GO that includes with or without hADSC cultures to span the defect and attach to the 
proximal and distal nerve stumps using 10-0 absorbable suture material (Figure 4.1).  
Negative control group (n=6) had 10 mm sections of sciatic nerve removed but did not receive any scaffold 
treatment. Positive control group (n=5) had sciatic nerve sections re-implanted to the distal and proximal 
stump using 10-0 vicryl sutures to mimic gold standard autologous peripheral nerve repair. The muscle 
tissue was returned to its original position and the skin was closed with 5-0 vicryl sutures. Each animal was 
administered buprenorphine (0.03 mg/kg; subcutaneous) every 6–12 hours for 72 hours and provided with 
free access to water containing Enrofloxacin (Baytril) oral antibiotics (100 mg/400 mL) and Gatorade 
powder for 72 hr. We applied E-collars to each rat for 24 hours post-surgery. This model of transecting the 
Sciatic nerve causes all animals to be affected by diminished use of the operated leg to various degrees over 
the duration of the study. This should not be interpreted as lameness or an indication of pain, but rather a 
result of the disability associated with the nerve model used. Signs of autotomy by the rats on the affected 
leg was also considered in our normal checkup of the rats as previous sciatic nerve studies have reported 
cases of potential self-mutilation most likely caused by abnormal sensations in the hind foot digits after 
transecting the sciatic nerve. 
 
 




4.2.3 VH4 Pressure Sensing Mat Assessment  
Gait patterns were analyzed using a pressure sensor mat (Tekscan VH4, Tekscan, Boston, MA) for each rat 
when they reach each 2-week interval post-surgery. The mat was prepared using the same tinted Plexiglas 
tunnel and Styrofoam borders to ensure the rats stay on the sensel areas during normal rat gait motion. The 
procedures for calibrating the, protocols for guiding rats to walk across the mat, and criteria for selecting 
successful runs are based on our previous gait comparison analysis between Sprague Dawley and Lewis 
rats referenced in chapter 3. All mean values for normalized body weight, and surface area contact from 
each successful trial was recorded to assess any changes in gait profiles that could indicate a return to 
function of motor and sensor endplates due to newly regenerated functional nerve tissue reaching the distal 
end of the sciatic nerve gap.   
4.2.4 Histology 
 At 12 weeks, the neural scaffolds and grafts were removed from the rats and aligned on sections of 
cardboard before being placed in 10% formalin to preserve the tissue sections. The tissues were embedded 
into paraffin and sliced longitudinally for histochemical analysis of the newly regenerated nerve tissues 
inside the nerve scaffolds extending from the proximal start to distal end. Based on the previous methods 
described by Carriel, Víctor, 2011 in the use of H&E and MCOLL histology methods for labeling layers of 
different tissue sections present in the peripheral nerve anatomy [5]. While H&E is a common method of 
staining for collagen tissues and the nucleus of cells, MCOLL staining involves the combined approach of 
using Luxofast Blue to stain for lipoproteins that should be found on the surface of myelin sheath tissue 
and Picrosirus Red stain for specific staining of different collagen tissues which makes up the majority of 
the perineurium and epineurium sections of peripheral nerves. This combination allows for clear 
identification of myelin sections present in newly regenerated nerve tissue for comparing the organization 
of myelin sections and their dimensions to that of native peripheral nerve tissue. 
4.3 Results 
4.3.1 PCL Neural Wrap Extraction 
96 % of the original 24 rat subjects made it to week 12 euthanasia. The study resulted in 6 Negative control 
rats, 5 autologous graft rats, 6 PCL+GO rats, and 6 PCL+GO+hADSC rats at week 12. One rat was removed 
due to complications during recovery post-surgery. No animal subjects showed any signs of discomfort of 





                Electrospun PCL+ GO              Electrospun PCL+ GO+ hADSC  
  
Figure 4.2 Week 12 neural wrap/conduit removal from Lewis rat subject’s post-euthanasia  
   Note: Stance Time, Stride Time, Stride Length, Stride Velocity, Maximum Force distribution, and surface contact area based on limb. 
 
All neural conduits and wraps extracted from animal subjects that reached week 12 in the study showed 
stable platforms with both ends securely attached to both the distal and proximal ends of the nerve gap. 
Neural wraps showed slight indications of early deterioration most likely due to hydrolyzes, on porous thin 
films. All neural wraps were extracted from all 12-week rats. Wraps, and autologous grafts were placed on 
cardboard sections then preserved in 10% formalin as histology slides. 
4.3.2 Gait Assessment of Lewis Rats During 12-Week Nerve Repair 
At pre-op and at each 2-week interval during nerve repair, each Lewis rat was placed on a Tekscan Pressure 
Mat system to assess the return of nerve function thru tracking of normal gait motion. Data pertaining to 
normal gait motion included maximum normalized force distribution, and surface contact area which were 
collected from both the right and left hind limbs as a means value. This gave us a profile of the rats’ gait in 













Table 4.1 Tekscan pressure mat raw data of mean temporal parameters 
Time Group Limb Stance_ 
time 




MF_BW MF_gr Max_ 
Peak_Pressure 
          
Week 2 
Negative 
LH 1.00±0.65 0.16±0.087 1.03±0.65 8.60±1.72 90.95±9.92 202.80±31.07 56.57±8.84 
RH 0.92±0.67 0.26±0.13 1.01±0.71 8.24±1.91 68.87±17.7 152.20±35.9 60.30±9.52 
Autologous 
LH 1.43±0.96 0.14±0.056 1.36±0.71 7.15±1.07 90.52±10.9 227.92±37.2 59.40±8.2 
RH 1.25±0.91 0.21±0.12 1.25±0.75 6.60±1.5 66.21±15.2 167.16±44.4 60.52±9.2 
PCL+GO 
LH 1.06±0.43 0.11±0.062 1.10±0.51 8.18±1.89 86.81±11.5 192.40±24.37 57.03±5.77 
RH 0.82±0.31 0.30±0.24 0.99±0.49 7.73±1.62 56.97±17.82 127.03±42.14 51.60±12.44 
PCL+GO+hMSC 
LH 0.84±0.52 0.13±0.037 0.83±0.57 8.32±1.25 85.12±14.11 196.0±35.18 56.17±9.61 
RH 0.67±0.4 0.24±0.11 0.75±0.44 7.62±1.58 58.78±12.85 135.17±30.32 54.37±8.68 
          
Week 4 
Negative 
LH 0.99±0.38 0.13±0.044 1.11±0.45 8.60±1.36 94.44±9.62 236.03±33.44 62.63±7.92 
RH 0.81±0.36 0.25±0.17 0.99±0.43 7.73±1.91 64.92±12.4 161.3±29.32 60.83±8.05 
Autologous 
LH 1.18±0.62 0.14±0.068 1.17±0.56 7.60±1.52 88.70±10.8 250.32±32.7 67.68±6.96 
RH 0.96±0.52 0.25±0.057 1.06±0.48 6.68±1.3 64.66±12.24 181.04±27.61 62.88±8.16 
PCL+GO 
LH 1.38±0.85 0.12±0.04 1.34±1.06 9.35±1.78 92.32±12.8 238.47±38.03 64.63±9.75 
RH 0.97±0.73 0.31±0.21 1.07±0.88 7.79±2.35 52.69±11.92 136.10±32.42 52.60±9.5 
PCL+GO+hMSC 
LH 1.05±0.6 0.12±0.056 1.13±0.76 8.41±1.83 86.43±19.12 237.43±56.6 63.17±10.62 
RH 0.84±0.46 0.21±0.11 0.89±0.51 7.25±1.83 55.32±21.1 150.17±54.5 54.43±15.0 
          
Week 6 
Negative 
LH 1.17±0.57 0.13±0.061 1.20±0.64 8.17±1.78 96.02±16.74 260.77±58.7 67.43±10.83 
RH 0.84±0.51 0.26±0.21 1.01±0.54 7.08±2.17 60.96±15.62 163.40±39.9 60.60±9.83 
Autologous 
LH 0.90±0.43 0.13±0.06 0.95±0.49 8.26±1.59 91.55±11.27 280.0±34.51 66.60±6.02 
RH 0.80±0.52 0.18±0.07 0.81±0.56 7.10±1.74 71.38±12.15 218.04±35.7 71.48±8.97 
PCL+GO 
LH 1.70±0.99 0.13±0.1 1.89±1.26 8.94±1.67 94.01±16.47 264.97±49.24 67.83±9.77 
RH 1.31±0.95 0.28±0.17 1.56±1.19 7.28±2.25 57.63±14.6 162.0±40.9 57.50±10.8 
PCL+GO+hMSC 
LH 1.24±0.77 0.12±0.05 1.26±0.7 8.55±1.66 91.23±15.93 273.07±51.14 67.83±9.16 
RH 0.95±0.71 0.27±0.13 0.96±0.56 6.67±1.3 57.66±15.2 171.67±43.09 57.63±11.7 
          
Week 8 
Negative 
LH 1.34±0.64 0.15±0.11 1.33±0.59 8.40±1.92 92.20±13.35 259.80±55.8 67.30±9.52 
RH 1.26±0.73 0.24±0.084 1.31±0.72 7.81±1.79 64.52±12.75 178.67±30.24 67.50±9.24 
Autologous 
LH 1.22±0.58 0.15±0.05 1.20±0.66 8.21±1.89 86.18±10.38 277.40±38.0 68.32±9.5 
RH 1.14±0.65 0.18±0.09 1.14±0.71 7.73±2.16 70.88±14.85 226.56±40.02 72.60±8.98 
PCL+GO 
LH 1.54±1.02 0.10±0.03 1.57±1.17 9.41±1.58 90.83±14.15 274.0±47.14 68.70±9.0 
RH 1.22±0.88 0.24±0.08 1.26±0.91 7.77±2.16 56.73±11.45 170.37±32.5 60.37±10.34 
PCL+GO+hMSC 
LH 1.01±0.47 0.11±0.043 0.89±0.56 8.99±1.75 95.87±13.9 303.90±41.61 72.03±7.98 
RH 0.79±0.35 0.25±0.17 0.77±0.41 8.53±3.28 56.70±19.65 179.70±61.7 59.83±14.73 
          
  










Table 4.1 Continued 
Time Group Limb Stance_ 
time 




MF_BW MF_gr Max_ 
Peak_Pressure 
  




LH 1.11±0.54 0.14±0.069 1.20±0.57 8.70±1.85 95.35±10.65 280.93±55.07 68.57±8.98 
RH 0.93±0.56 0.19±0.096 0.98±0.53 7.38±1.99 64.04±13.25 186.13±36.51 67.60±9.36 
Autologous 
LH 0.90±0.39 0.14±0.05 0.97±0.47 9.18±1.89 91.48±8.53 308.72±35.93 71.92±7.75 
RH 0.78±0.32 0.16±0.065 0.79±0.36 7.84±1.37 72.32±9.92 243.0±29.35 75.56±8.22 
PCL+GO 
LH 1.16±0.56 0.13±0.13 1.25±0.67 9.56±1.84 91.14±13 286.60±42.39 71.37±7.12 
RH 0.88±0.45 0.27±0.16 1.01±0.56 8.21±2.34 58.27±16.51 183.80±53.62 64.40±12.87 
PCL+GO+hMSC 
LH 0.99±0.4 0.11±0.045 0.85±0.37 8.54±2.19 91.54±12.09 304.83±48.19 68.97±9.66 
RH 0.81±0.35 0.22±0.098 0.81±0.38 7.52±1.78 58.64±12.78 194.07±40.42 66.80±12.27 




LH 1.23±0.55 0.12±0.046 1.24±0.56 8.46±1.23 92.55±11.34 285.77±57.39 70.10±8.14 
RH 0.95±0.44 0.21±0.076 0.99±0.53 7.18±2.03 60.03±9.54 184.33±36.25 68.53±10.58 
Autologous 
LH 0.81±0.32 0.14±0.064 0.86±0.43 9.10±2.05 85.44±9.63 299.76±44.91 71.36±7.63 
RH 0.62±0.26 0.16±0.11 0.68±0.31 7.23±1.26 66.58±10.3 232.56±36.86 72.80±7.39 
PCL+GO 
LH 0.84±0.3 0.10±0.026 0.81±0.33 9.05±1.9 84.62±11.6 283.50±42.5 73.37±8.3 
RH 0.71±0.32 0.19±0.057 0.69±0.33 7.99±1.98 58.12±9.68 193.90±30.88 66.40±9.37 
PCL+GO+hMSC 
LH 1.04±0.68 0.12±0.038 0.91±0.65 9.40±1.97 91.90±9.59 318.47±38.23 71.40±6.41 
RH 1.00±1.0 0.21±0.059 0.94±0.98 8.37±2.19 64.81±12.06 223.70±38.87 70.60±10.36 
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In order to compare these results between each group given that each rodent is independent from all other 
rodents in the sample size it is essential that we normalize the results as a ratio between the hind limbs 
impacted by the neural defect (right hind limb) and the control hind limb with no neural defect impact left 
hind limb). Table 4.2 compares the mean surface area contact and normalized body weight ratios over the 
period of 12 weeks of nerve repair using the pre-surgery time point (week 0) as the base line for fully 
functional nerves. A value close to 0 indicates LH and RH hind limb values that are similar to each other 
in terms of either the surface area contacts or force distribution in the hind limbs.  
 
Table 4.2 Mean ratios of hind limbs mean  
 Autologous 
 Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
SAC 0.036766 0.624656 0.657499 0.596527 0.600062 0.542816 0.487804 
BW max 0.019401 0.367206 0.371938 0.282616 0.215733 0.264808 0.283345 
        
 PCL+GO 
 Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
SAC 0.072203 0.881526 0.944491 0.887065 0.979261 0.809786 0.708114 
BW max 0.021006 0.523932 0.752135 0.631211 0.601034 0.563951 0.45587 
        
 PCL+GO+hMSC 
 Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
SAC 0.034916 0.838589 0.921013 0.904774 1.034102 0.957124 0.734144 
BW max 0.043607 0.448086 0.562425 0.582355 0.69087 0.560962 0.417867 
        
 Negative 
 Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
SAC 0.026312 0.649361 0.690812 0.826862 0.753592 0.820436 0.759931 
BW max 0.015267 0.320492 0.454587 0.57499 0.42894 0.488836 0.541729 
        









Autologous, normal Lewis rat sciatic nerve section, and nerve wrap tissue samples were removed from 10% 
formalin solution and embedded in parafilm. Tissue samples were oriented in order to cut longitudinal 
histology sections of the tissue to visualize the organization and distance of new tissue growth thru the 
nerve scaffold across the length of the critical defect. MCOLL staining of longitudinal sections from each 
euthanized rat was carried out and images from 1 random rat subject from each group was assessed under 
light microscopy with images taken at 4x and 40x magnification at 5 specific areas along each tissue section. 
These areas were determined by establishing areas at the two ends of the longitudinal sections as the 
proximal and distal ends and half way in between as the center position. Areas between the two ends and 
the center area were labeled as proximal center and distal center positions.    
 
 
Distal Distal_Center  Center Center_Proximal Proximal 
Normal 
Sciatic nerve 
     
Autologous 
     
PCL+GO 
     
PCL+ 
GO+hADSC 
     
Figure 4.5 Week 12 MCOLL staining  




4.3.4 Luxofast Blue Coverage/Myelin Diameter 
20x magnification MCOLL images at all areas of the longitudinal histology sections excluding the distal 
areas were used to assess luxofast area coverage. A lack of luxofast blue staining present at the distal stump 
for all tissue sections besides the normal sciatic nerve tissue is most likely due to new nerve growth not 
having reached the distal stump by 12 weeks of nerve repair in the nerve wrap groups. 20x images from the 
proximal region to the distal center region was processed thru ImageJ to grey scale luxofast blue to 
determine its area coverage across each of these regions as a positive stain for myelin tissue (Figure 4.6). 
5 random areas in each 20x image was selected for luxofast blue area coverage. This resulted in a total of 
20 data points for 1 histology section from each repair group with no replicates. (Figure 4.7).  
Results showed that the normal sciatic nerve had the highest luxofast blue stain coverage across the entire 
span of the tissue section indicating a potential large presence of myelin tissue in native Lewis rat sciatic 
nerves. The Gold standard autologous group showed significantly lower levels of luxofast blue coverage at 
12 weeks repair compared to all other groups tested. PCL+GO and PCL+GO+hADSC experimental nerve 
wraps showed luxofast blue coverage significantly greater than the autologous group with the PCL+GO 
groups showing coverage comparable to that of the native nerve tissue.  
40x magnification MCOLL images from 3 selected areas of the longitudinal histology sections excluding 
the distal area was selected for the presence of intense luxofast blue intensity organized into characteristic 
myelin sheath dimensions as described in previous studies using MCOLL staining on peripheral nerves. 
Using ImageJ, lines were drawn transecting the axons perpendicular to the axonal axis of the myelin 
sections. Diameters of myelin sections at their widest point were recorded at random areas in each 40x 
image to assess myelin thickness by 12 weeks nerve repair. This resulted in a total of 30 data points for 1 








Figure 4.6 ImageJ grey scaling of luxofast blue staining of myelin sheath  
Note: Quantified myelin area coverage for each group at week 12 extraction. 
 
 



















































Figure 4.8 Myelin diameter assessment: tracking for presence of myelin tissue at week 12  
 
Results showed that the normal sciatic nerve had the highest myelin sheath thickness compared to all other 
groups tested. The Gold standard autologous group showed significantly lower myelin thickness at 12 
weeks repair compared to all other groups tested. PCL+GO and PCL+GO+hADSC experimental nerve 
wraps showed myelin sheath diameters significantly greater than the autologous group by week 12 with 
expected new immature myelin tissue to be in abundance around the experimental nerve wraps.   
4.4 Discussion 
3D PCL fiber meshes coated with GO were successfully created using slightly modified manufacturing 
protocols from previous In-vitro study. Films selected to support hADSC growth were confirmed to have 
cell culture growth thru DiI staining 24 hours prior to film implant. The study lost one Lewis rat due to 
complications during recovery. 
Temporal data of rats did not show signs of significant changes during the 12-week period of nerve 
regeneration. Force distribution and surface area contact ratios between the right and left hind limbs were 
found to be significantly similar to each other at pre-surgery time points for all rodent groups. After sciatic 
nerve transection, the ratios for force distribution and surface area contact between the hind limbs was 



































involving transecting a section of the Sprague Dawley spinal cord that affected the right leg only and 
recorded both the pre-surgery and post-surgery changes in gait parameters for both hind limbs using the 
same system and software used in the study [6]. Results comparing surface area contact and body weight 
distribution between all experiment groups showed that by week 12 no group ratio values for either surface 
area contact and body weight distribution parameters was significantly similar to the base line ratios. This 
would suggest that the repair groups implemented to repair a 10 mm sciatic neural defect in Lewis rats did 
not reach full functionality by 12 weeks In-vivo  
MCOLL staining of tissue sections showed positive staining on control normal sciatic nerve sections with 
clear tissue organization similar to that of previous longitudinal histology sections of peripheral nerves 
stained with MCOLL. This type of organization was also present along the regions of PCL+GO and 
PCL+GO+hADSC nerve wrap experimental groups. Identification of neural wrap tissue sections stained 
with luxofast blue, and picosirus red was not clear in all sample tissues stained. PCL+GO nerve wrap with 
and without the inclusion of hADSC showed nonspecific staining of other tissue components present in the 
neural defect that could not be identified at present. Peripheral nerve anatomy structures are not as 
pronounced as what is shown in normal sciatic nerve tissue sections. Autologous clinical gold standard 
showed minimal expression of luxofast blue staining across all regions indicating a potential lack of myelin 
tissue in new regenerating tissue by 12 weeks. High density of hematoxylin staining for cell nucleus is 
present in all experimental groups compared to the normal sciatic nerve groups most likely due to the 
intrusion of fibroblasts, Schwann cells, and macrophages to regulate endogenous nerve repair.   
Quantitation of luxofast blue surface coverage in histology images showed normal sciatic nerves had the 
highest coverage of luxofast blue staining. This is most likely attributed to its abundance of mature and 
developed myelin sections present in the native peripheral nerves. Autologous showed the lowest coverage 
of luxofast blue, indicating that newly regenerated myelin sheath production has not started by week 12. 
The neural wrap design both with and without hADSC showed statistically greater coverage of the stain 
than the autologous group, with the neural wraps without hADSC cultures showing stain coverages almost 
comparable to that of normal sciatic nerve tissue. This would suggest that new myelin sheath production 
has started along the length of the neural wrap. 
Quantitation of the diameter of myelin sections showed that normal sciatic nerves had the highest myelin 
sheath diameter sections. This is most likely due to that most of the myelin present in native sciatic nerve 
tissue is mature and well developed as a thick myelin sheath. Autologous showed the lowest myelin sheath 
diameter, indicating that newly regenerated myelin sheath production has not started by week 12. The neural 
wrap design both with and without hADSC showed statistically greater myelin sheath diameter sizes than 




4.4.1 Implications/Challenges    
Sciatic nerve defect model The selection of the animal subjects regarding strain of rats was initially using 
Sprague Dawley rats. However, these strains were found to be very susceptible to sensations in the hind 
limbs after transecting the sciatic nerve eventually leading to them self-mutilating their affected hind limbs 
in a behavior pattern known as autotomy. The study started out with 17 total Sprague Dawley rats following 
the protocols stipulated in IACUC# 2574-0318. 70.6% of the Sprague Dawley population was affected by 
autotomy behavior during different time points of the 12-week nerve repair. Multiple methods were 
considered to try and reduce the onset of autotomy behavior including the use of bitter apple and 
metronidazole coatings to dissuade biting at the effected hind limbs. These methods showed no indications 
of improving or preventing autotomy as the study progressed. It was decided to change the strain of the rat 
subjects to Lewis rats due to their recorded history of showing less autotomy behavior in neural defect 
models. 100% of the Lewis rat population showed no signs of autotomy throughout the entire duration of 
nerve repair. 
Multiple passes were needed from each rat to achieve the required 5 successful walks to be assessed for 
gait analysis. The ease of handling of Lewis rats on the gait pressure mat could be improved if the rodents 
are given an extended period of time to adjust and trained to use the mat system to reduce the number of 
false walks or passes on the pressure mat during data collection. This can also be managed by making 
appropriate modifications to the pressure mat design by installing higher border sections at the sensel edges 
and smaller tunnel dimensions so that the rats can’t walk off the mat or stand on their hind limbs while 
recording gait.  
 Histology While the MCOLL staining method did well in establishing the presence of new tissue growth 
in the biomaterial without any observable interference from the scaffold. The non-specificity of the stain 
makes it difficult to identify with confidence the types of tissue that stains with the MCOLL. Other more 
specific staining methods are needed to evaluate specific components of newly regenerated nerve tissue 
such as staining for specific myelin sheath protein 0 or specific axon protein markers β 3 tubulin, or GAP-
43. Embedding aligned tissue sections in parafilm sections were made difficult by the thin film 
characteristics of the biomaterial. Longitudinal cuts of the tissue sections potentially missed large sections 
of tissue across the length of the neural scaffold. The additions of cross-sectional cuts would also assist in 
identifying the exact location of new tissue growth relative to the biomaterial.  Multiple layered cuts of the 
tissue are needed in order to make a complete assessment of the materials potential for new tissue growth. 
Histology assessment concerning data on stain intensity and tissue dimensions between different repair 




stained with MCOLL as replicates to further improve the statistical confidence of the data. Current 
measurements concerning luxofast blue and myelin sheath diameter would not be publishable if they came 
from tissue sections of just one rat replicate. More specific measurements of the tissue sections dimensions 
such as tissue length and size will make locating regions on the tissue more precise as opposed to simply 
saying the proximal, or center region. This will also improve the precision of selecting areas in these regions 
for data measurements as opposed to saying the top left corner of the proximal region was assessed for 
myelin sheath dimensions. Quantitative intensity assessment of nonspecific luxofast blue staining was 
subjective with each image to maximize intensity of the myelin sections while minimizing the intensity of 
other nonspecific tissues stained with luxofast. This emphasizes the need to stain for specific markers rather 
than nonspecific surface properties to identify and measure tissues we expect to be present in regenerating 
nerves.  
Manufacturing The initial PCL with GO surface coatings of this In-vivo study had similar characteristics 
to the PCL fiber meshes created in the manufacturing phases of the In-vitro study discussed in chapter 2. 
Similar to our discussions in this chapter, it also determined that the ease of handling these 3D biomaterials 
of similar fiber designs after being placed in a wetted environment was difficult to manage in both the initial 
assessment of visualizing hADSC cultures on the material surface after 24hours incubation and positioning 
the biomaterials in at the neural defect site during surgery. Slight modifications in the electrospinning 
protocol by reducing the voltage and reducing the distance of spinning produced PCL fiber meshes that 
were more rigid and less able to fold on itself making visualization and handling in surgical settings easier 
to manage. 
 Gait analysis The pressure mapping system detected differences in hind limb force distribution and surface 
area contact to assess the return of neural functions. As an acceptable indirect format for evaluating return 
of nerve function it is necessary to note that these results might not correlate well to more direct approaches 
to evaluating nerve function such as electrophysiology and histomorphometric analysis. One of the most 
common indirect methods for assessing nerve function in the sciatic nerve of rodents is the standard Sciatic 
Function Index (SFI). Studies have shown that the SFI is highly correlated to that of direct methods for 
assessing nerve function including histomorphometric analysis. It would be a beneficial component to this 
study to use SFI assessment in tandem with the Pressure mapping system to bridge the results of the gait 
analysis to that of the histology results to determine if a correlation is present. 
The results from this study leave many questions concerning how the new tissue develops and grows at 
different time points and whether they correlate to the gait patterns at these time points as well during the 
nerve repair cycle. This suggests that the design of this experiment should be altered to euthanize a number 




assessment of the how the new tissue grows on the nerve wrap and see if a correlation exist between the 
growth pattern and the gait pattern. It might also be prudent to extend the period of nerve repair to a further 
time period to see if the gait pattern of or neural wraps will eventually become significantly similar to the 
baseline values that would indicate a return of full functionality of the sciatic nerve.  
It is also unclear what impact that hADSC therapy had at repairing the critical nerve defect in rats when 
cultured onto the neural wrap design. It is expected by week 12 that the exogenous hADSC cultures will 
have been removed by the rat physiology, but no clear indications of the cells impact at the injury site are 
obvious when assessing both gait and histology data. As suggested before it might be beneficial to divide 
rats in each group to be euthanized at early stages of nerve repair to increase the chances of observing how 
these cells respond in this type of environment and what immediate or lasting impact they might have on 
the repair of neural defects.  If future studies plan to move toward this setup, it is imperative that methods 
for tracking these cell cultures In-vivo are utilized and careful extraction of the tissue so as to not disrupt 
any remaining live cells for analysis, such as staining for specific human markers to differentiate between 
cells of human origin from native exogenic tissue. The decision to keep cell cultures allogenic or exogenous 
must also be considered as is likely that allogenic cultures will survive longer and provide more therapeutic 
effects at the injury site compared to exogenous therapy.    
4.5 Conclusion 
We have described the first initial set of In-vivo data supporting our hypothesis as a step towards further 
developing synthetic 3D PCL fiber GO coated wraps for consideration into clinical trials. Our assessment 
determined that PCL platforms of thin film nano-fibers surface coated with GO in combination with or 
without hADSC line cultures were capable of supporting new tissue that mimics closely in tissue layering 
and orientation to that of native peripheral nerve tissue at different areas of the neural scaffolds. Indirect 
gait analysis of the rats over the period of recovery showed significant differences in the gait of the rats 
after transection of the sciatic nerve in terms of weight distribution and surface area contact ratios between 
the hind legs. By week 12 of neural repair, all repair groups showed significant differences in weight 
distribution and surface area contact ratios compared to the pre-surgery baseline values, indicating full 
recovery of sciatic nerve defects had not been reached by week 12. Pressure map systems cannot discern 
the potential implication of asymmetrical pattern and behavior inherent in complex physiological systems. 
To determine if this data is dependent or not on the nerve injury induced in the rats, the end period time 
point should be extended to a later date to see if these patterns persist or subside according to what is 
expected. Direct histochemical staining of each group confirmed the presence of new tissue at multiple sites 




nerve tissue. Neural wraps had additional tissue growth that were non-specific to the MCOLL stain making 
areas of the tissue difficult to clearly differentiate organization that is expected in native neural tissue. All 
iterations of the nerve wrap showed signs of extensive growth thru the scaffolds at 12 weeks of neural 
healing, with potential signs of early myelin sheath production occurring along the length of the material 
compared to the gold standard autologous.   
The results of this study suggest that PCL fiber meshes with GO surface coatings with or without the 
addition of hADSC cultures were successful in supporting new tissue growth and possibly assisting in 
guidance of new tissue across the peripheral nerve defect. Based on our histochemical nonspecific staining 
for myelin and collagen tissue in native peripheral nerve and the organization of this tissue leads us to 
suggest that the new tissue is most likely new peripheral nerves that are extending from the proximal stump 
with endogenous repair and support being provided by the neural wraps. It is suggested that the next phase 
of In-vivo assessments use the same rodent small animal model but extend the time of the study to ensure 
that new tissue reaches the distal stump, with the addition of other direct methods for assessing neural 
function such as electrophysiology and staining for more specific nerve markers. These additions should 
help us determine with a higher degree of confidence that the new tissue is in fact new peripheral nerves 
and whether it is active nerve segments capable of propagating their own electrical signals without 
assistance. This should also determine if we can correlate the pressure map system data to that of data 
established from direct methods for assessing neural function as new neural tissue reaches the distal stump. 
Further studies may involve making alterations to these scaffold designs such as improving tracking of 
hADSC cultures In-vivo, better techniques for improving the amount of MSC seeded to the PCL platforms, 
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5.1 Final Remarks 
This body of work represents the careful steps and assessments required to determine proof of concept and 
functionality in the early stages of developing novel tissue engineering devices. This study has resulted in 
the successful manufacturing of a neural wrap material composed of electrospun nanofiber PCL matrices 
with surfaces modified by thin coating GO films by air spray methods to support hADSC therapies. This 
design was pursued in an attempt to address the problem of inadequate repair of critical size defects in the 
peripheral nerves of trauma patients. The design was created to function as a conduit bridge across the 
defect gap that will deliver hADSCs to the site of injury while guide and stimulate early axon regeneration 
that would culminate in early and or improved tissue repair. Early In-vitro studies showed that this 
biomaterial was biocompatible to MSC cultures and could support hADSC cultures for up to 6 days in 
culture while hADSCs were artificially stimulated towards neural-like lineages. To assess the In-vivo 
potential of this biomaterial design a rat sciatic nerve defect model that simulates a critical size neural defect 
expected in patients with severe neurotmesis was utilized. The wraps were sutured to the defect site and 
left In-vivo for 12 weeks to provide assistance in repairing of the neural defect. At 12 weeks it was found 
that the wraps could support and guide new tissue growth along the longitudinal axis of the neural defect 
site both with and without hADSC cultures. This suggests that nanofiber PCL+ GO surface coating material 
iterations might be a suitable candidate for further preclinical studies in developing biomaterial wraps 
designed to assist in critical nerve defect repairs. 
While this material has shown great potential in supporting new tissue growth In-vivo, further preclinical 
studies are needed to determine the materials effectiveness at specifically supporting and stimulating growth 
of axons as a targeted therapy approach. This involves tweaking the design of the material based on the 
suggested improvements and complications addressed in the In-vivo study, and altering the experimental 
design of the In-vitro tests to address the complications noted there. Of primary concern is to determine 
what type of therapy hADSC cultures have during the initial stages of nerve repair and whether their 
presence significantly improves or has a neutral or insignificant affect on neural regeneration. By carefully 
considering the appropriate neural cell line to co-culture with hADSCs and further control for specific 
extracellular compounds present during endogenous nerve repair, we can see how hADSC cultures will 
behave as an early look at what types of therapy effects hADSC cultures might express In-vitro. In the In-
vivo study if we euthanize rats at earlier time points, we might be able to track the stem cells as the new 
nerve tissue regenerates. We can also use this time to look for specific neural markers expressed during 
axonal growth and improve techniques in handling rodent subjects during gait analysis and techniques for 




One other complication of concern is determining whether the gait parameters measured during the In-vivo 
study can be correlated to the histology results at their respective time points. By using in conjunction to 
our pressure mat another indirect method that has been well established as having a high correlation to 
histology results when assessing a return of nerve function, there would be a greater chance of establishing 
a correlation pattern if one exists. The Sciatic Function Index (SFI) method is the most commonly used and 
reported method in conjunction with histomorphology results, with a high record of these reports stating a 
high correlation to histology results. 
As I conclude this study, I am reminded of the prodigious responsibility that tissue engineers owe to the 
people we serve. While it is often enough to simply follow the standards and guidelines of assessing new 
devices, I feel it is our obligation to remind ourselves to why we follow them. Medical devices are some of 
the most dangerous items available to the market. A device specifically engineered to function with or 
within a system that is not yet fully understood, where stimulation from a medical device can cause a 
cascading effect that if not corrected could have severe acute or long-term effects on a person’s health or 
wellbeing. These standards are in place more so to protect the customers who trust that our products will 
target to resolve their immediate or future medical related problems without causing complications in the 
form of new medical problems. As engineers, scientist, researchers, and inventors it is our duty to discover, 
create, and seek out new and innovative ideas/products out of the public’s interest or our own, but I feel 
that it is our responsibility to always actively seek out and pursue faults in our ideas and designs. This is 
more relevant today than in any other period in history for developing medical devices. With the rate at 
which new technologies are being developed comes the need to revise the current standards to assess how 
these new technologies will impact the public’s health should they be used in developing new medical 
devices. By critiquing ourselves, we indirectly proclaim to the public that it is in our concern for their 
wellbeing as the reason why we develop medical devices in the first place. This will only further our creed 
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